Institutes
Refine
Year of publication
- 2021 (662) (remove)
Document Type
- Article (613)
- Preprint (32)
- Conference Proceeding (11)
- Doctoral Thesis (6)
Language
- English (662) (remove)
Has Fulltext
- yes (662) (remove)
Is part of the Bibliography
- no (662)
Keywords
- SARS-CoV-2 (23)
- COVID-19 (20)
- inflammation (12)
- prostate cancer (9)
- autophagy (8)
- Epilepsy (7)
- survival (7)
- ADHD (6)
- breast cancer (6)
- radical prostatectomy (6)
- tumor microenvironment (6)
- Genetics (5)
- aging (5)
- apoptosis (5)
- children (5)
- endothelial cells (5)
- mortality (5)
- outcome (5)
- risk factors (5)
- Cancer (4)
- Heart failure (4)
- Immunotherapy (4)
- Neurology (4)
- ROS (4)
- Risk factors (4)
- acute myeloid leukemia (4)
- angiogenesis (4)
- chemotherapy (4)
- epilepsy (4)
- extracellular matrix (4)
- gene therapy (4)
- hypoxia (4)
- iron (4)
- iron deficiency (4)
- oxidative stress (4)
- prevalence (4)
- stroke (4)
- targeted therapy (4)
- vaccination (4)
- 177Lu-PSMA-617 (3)
- Acute myeloid leukemia (3)
- Alcohol (3)
- Angiogenesis (3)
- Apoptosis (3)
- Biochemistry (3)
- Bipolar disorder (3)
- Cell biology (3)
- Diagnostic markers (3)
- EEG (3)
- Edema (3)
- Immunology (3)
- IntelliCage (3)
- Medical research (3)
- Melanoma (3)
- Microbiology (3)
- Molecular biology (3)
- Mortality (3)
- NK cells (3)
- Outcome (3)
- PSMA (3)
- Proteomics (3)
- Quality of life (3)
- Radiotherapy (3)
- Seizure (3)
- Surgery (3)
- Survival (3)
- VEGF (3)
- adverse events (3)
- biomarker (3)
- bladder cancer (3)
- cancer (3)
- cirrhosis (3)
- data science (3)
- dentate gyrus (3)
- epidemiology (3)
- exosomes (3)
- external beam radiotherapy (3)
- fMRI (3)
- glioblastoma (3)
- haemophilia care (3)
- haemophilia treatment (3)
- immune cells (3)
- immunotherapy (3)
- influenza (3)
- liver (3)
- liver cirrhosis (3)
- lung cancer (3)
- macrophage polarization (3)
- macrophages (3)
- metastasis (3)
- metastatic prostate cancer (3)
- pediatric (3)
- proliferation (3)
- toll-like receptor (3)
- treatment (3)
- treatment centres (3)
- 3D printing (2)
- ALK (2)
- Acuris (2)
- Acute lymphoblastic leukemia (2)
- Adenocarcinoma (2)
- Age estimation (2)
- Anemia (2)
- Angiography (2)
- Ataxia-telangiectasia (2)
- Attitude (2)
- Autopsy (2)
- BAG3 (2)
- BCOR (2)
- BPH (2)
- Bacterial infection (2)
- Behavior (2)
- Blood (2)
- Blood loss estimation (2)
- Blow flies (2)
- Bone density (2)
- Bone marrow (2)
- Brain (2)
- Breast cancer (2)
- Burden of illness (2)
- CD14 (2)
- COVID 19 (2)
- CRM (2)
- CSM (2)
- Cancer-specific mortality (2)
- Cardiovascular diseases (2)
- Cell culture (2)
- Cesarean section (2)
- Chronic kidney disease (2)
- Cirrhosis (2)
- Collagen (2)
- Corona (2)
- DMEK (2)
- Dental implant (2)
- Depression (2)
- Dravet syndrome (2)
- ER stress (2)
- EWSR1 (2)
- Endocannabinoid (2)
- Endocrinology (2)
- Entscheidungsassistenz (2)
- Environmental support (2)
- Epidemiology and End Results (2)
- Fasting (2)
- Forensic medicine (2)
- Gene fusion (2)
- Gene regulation (2)
- Gleason score (2)
- Glioblastoma (2)
- Glucose (2)
- Health care (2)
- Healthcare costs (2)
- Human behaviour (2)
- Hypertension (2)
- Induction chemotherapy (2)
- Infection (2)
- Inflammation (2)
- Intensive care treatment (2)
- Intensive care units (2)
- Interleukin-6 (2)
- Ketogenic diet (2)
- Labor and delivery (2)
- Leptin (2)
- MRI (2)
- Machine learning (2)
- Medical consultation (2)
- Medical risk factors (2)
- Model (2)
- Multidetector computed tomography (2)
- NADH dehydrogenase (2)
- NADPH oxidase (2)
- NCCN (2)
- NF-κB (2)
- Neuroscience (2)
- Osteoporosis (2)
- PCR (2)
- Pandemic (2)
- Pathogenesis (2)
- Patient blood management (2)
- Patient needs (2)
- Patientenbedürfnisse (2)
- Pediatric (2)
- Penile cancer (2)
- Periodontal treatment (2)
- Person-Umwelt-Passung (2)
- Person-environment fit (2)
- Physical activity (2)
- Physiology (2)
- Platelet-rich fibrin (2)
- Point-of-care testing (2)
- Portal hypertension (2)
- Post-mortem interval (2)
- Pregnancy (2)
- Preterm birth (2)
- Prevalence (2)
- Prognostic tool (2)
- Prophylaxis (2)
- Prostate cancer (2)
- Pulmonary embolism (2)
- Radiation (2)
- Rare diseases (2)
- Research Article (2)
- SCC (2)
- SV2A (2)
- Sensitivity (2)
- Specificity (2)
- Spine (2)
- Squamous cell carcinoma (2)
- Status epilepticus (2)
- Suicide (2)
- Supported decision making (2)
- Surveillance (2)
- Systemic inflammation (2)
- Systemic therapy (2)
- TSC (2)
- Tomography (x-ray computed) (2)
- Tooth loss (2)
- Trauma (2)
- Treatment (2)
- Treatment outcome (2)
- Ultrasound (2)
- Undergraduate medical education (2)
- Unterstützung der Umwelt (2)
- Usability (2)
- Variant histology (2)
- Visual estimation (2)
- alcohol use disorder (2)
- anemia (2)
- animal experiments (2)
- antibiotic resistance (2)
- antiviral therapy (2)
- bibliometrics (2)
- biomarkers (2)
- biopsy cores (2)
- bleeding (2)
- bortezomib (2)
- brain cancer (2)
- cancer-specific mortality (2)
- cell cycle (2)
- cell migration (2)
- cerebrospinal fluid (2)
- cesarean section (2)
- child (2)
- childhood acute myeloid leukemia (2)
- chronic kidney disease (2)
- clinical trial (2)
- clinical trials (2)
- colon cancer (2)
- complexome profiling (2)
- computed tomography (2)
- contemporary (2)
- coronavirus (2)
- critical care (2)
- dexamethasone (2)
- diabetes (2)
- diabetes mellitus (2)
- diagnostic algorithm (2)
- drug resistance (2)
- efficacy (2)
- elderly (2)
- electrophysiology (2)
- epigenetics (2)
- epithelial to mesenchymal transition (2)
- ergonomics (2)
- executive function (2)
- extracellular vesicles (2)
- fibroblasts (2)
- follow-up (2)
- furcation involvement class III (2)
- fusion biopsy (2)
- heart (2)
- heart failure (2)
- hematopoietic stem cell transplantation (2)
- homeostatic plasticity (2)
- innate immunity (2)
- intermediate risk (2)
- iron metabolism (2)
- kidney (2)
- kidney cancer (2)
- levetiracetam (2)
- lipocalin-2 (2)
- liver transplantation (2)
- lncRNA (2)
- localized prostate cancer (2)
- long-term tooth survival (2)
- lymph node dissection (2)
- machine learning (2)
- macrophage (2)
- magnetic resonance imaging (2)
- mast cells (2)
- metastatic castration-resistant prostate cancer (2)
- miRNA (2)
- microRNA (2)
- microglia (2)
- multiple sclerosis (2)
- ncRNA (2)
- neurocognitive (2)
- neuropathic pain (2)
- neutralizing antibodies (2)
- niche (2)
- oligomerisation (2)
- osteoarthritis (2)
- other-cause mortality (2)
- out-patient paediatrics (2)
- overall survival (2)
- oxidative phosphorylation (2)
- p53 (2)
- pain (2)
- patients (2)
- pediatric patients (2)
- pentose phosphate pathway (2)
- perception (2)
- periodontitis stage III and IV (2)
- pharmacokinetics (2)
- phosphorylation (2)
- platelets (2)
- pneumonia (2)
- portal hypertension (2)
- primary care (2)
- primary cilium (2)
- primary prostate cancer (2)
- questionnaire (2)
- radical prostatecomy (2)
- radiotherapy (2)
- receptor (2)
- refractory (2)
- regenerative medicine (2)
- relapse (2)
- residual myometrial thickness (2)
- respiratory chain (2)
- respiratory tract infection (2)
- salvage therapy (2)
- second-line (2)
- seizure (2)
- spine head (2)
- status epilepticus (2)
- strength training (2)
- stress (2)
- stress granules (2)
- supportive periodontal therapy (2)
- surgery (2)
- synaptic plasticity (2)
- synaptopodin (2)
- systematic biopsy (2)
- systemic antibiotics (2)
- thrombolysis (2)
- thrombosis (2)
- tissue engineering (2)
- tooth loss (2)
- triple-negative breast cancer (2)
- tumor necrosis factor (2)
- tumor-associated macrophages (2)
- tyrosine kinase inhibitors (2)
- ubiquitination (2)
- urological cancer (2)
- very high risk (2)
- working memory (2)
- Ärztliche Aufklärung (2)
- (sub-) luxation (1)
- 1-propanol (1)
- 2-AG (1)
- 2-Arachidonoyl glycerol (1)
- 2-deoxy-d-glucose (1)
- 26 LncRNA (1)
- 2′,3′-cGAMP (1)
- 3-year survival (1)
- 3D gait analysis (1)
- 3D printing using composite resin (1)
- 3D printing using zirconia (1)
- 3D rapid prototyping (1)
- 3T3-L1 mouse fibroblasts (1)
- 5-lipoxygenase (1)
- ABCB5 (1)
- ACE inhibitor (1)
- ACLF (1)
- ADAM15 (1)
- ADCC (1)
- AGMO (1)
- AIDS (1)
- AKT (1)
- AKT signaling (1)
- ALD (1)
- ALDH2 (1)
- AML (1)
- AO-PCCF (1)
- APT-CEST (1)
- ARDS (1)
- AT1 receptor antagonist (1)
- ATG3 (1)
- AU-rich element (1)
- Accidents (1)
- Acinetobacter baumannii (1)
- Acquired resistance (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute inflammation (1)
- Acute kidney failure (1)
- Acute kidney injury (1)
- Acute respiratory distress syndrom (1)
- Adiposity (1)
- Adults (1)
- Advanced stage (1)
- Adverse effects (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Affective Misattribution Procedure (1)
- Ag-RDT (1)
- Aganglionosis (1)
- Aging (1)
- Albumin (1)
- Algorithms (1)
- Alpha power (1)
- Alpha-fetoprotein (AFP) (1)
- Alzheimer's disease (1)
- Amblyopia (1)
- Amino acids (1)
- Amniotic fluid (1)
- Amphetamine (1)
- Analysis tool (1)
- Anandamide (1)
- Anemia management (1)
- Angiomyolipoma (1)
- Angststörungen (1)
- Animal disease models (1)
- Animal experiment (1)
- Animal models (1)
- Anti-seizure medication (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Antibody avidity (1)
- Anticonvulsant (1)
- Antimicrobial treatment (1)
- Antiretroviral therapy (1)
- Anwendbarkeit (1)
- Anxiety (1)
- Apoptotic cell death (1)
- Ara h2-specific IgE (1)
- Artificial intelligence (1)
- Asparaginase (1)
- Aspergillus (1)
- Astrocytoma (1)
- Ataxia telangiectasia (1)
- Atomoxetine (1)
- Attention (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Autism (1)
- Autism Spectrum disorder (1)
- Autism spectrum disorder (1)
- Autologous biomaterial (1)
- Ayurveda (1)
- B cells (1)
- B-cell transcription factors (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BCORL1 (1)
- BCX7353 (1)
- BEACOPP (1)
- BMI (1)
- BMNC (1)
- BNT162b2 (1)
- BNT2b2 (1)
- BPO (1)
- BPTF (1)
- BRD4 (1)
- Back scan (1)
- Bacterial leakage (1)
- Barrier (1)
- Bartonella grahamii (1)
- Bartonella henselae (1)
- Bartonella schoenbuchensis (1)
- Basal ganglia (1)
- Beckwith–Wiedemann syndrome (1)
- Behandlungspfad (1)
- Behavioural ecology (1)
- Berotralstat (1)
- Bevacizumab (1)
- Big Five (1)
- Bio safety (1)
- Biofilm (1)
- Biological profile (1)
- Biomarker (1)
- Biomarkers (1)
- Biophysical models (1)
- Biophysics (1)
- Biopsy (1)
- Birth (1)
- Birth weight (1)
- Bleeding (1)
- Blood coagulation disorder (1)
- Blood loss calculator (1)
- Blood loss formula (1)
- Blood management (1)
- Blood plasma (1)
- Blood sampling (1)
- Blutungskontrolle (1)
- Body sway (1)
- Bone cement implantation syndrome (1)
- Bone diseases, Metabolic (1)
- Bone metastases (1)
- Bowel obstruction (1)
- Bradycardia (1)
- Brain metastasis (1)
- Brain tumor (1)
- Browsertool (1)
- Burkitt’s lymphoma (1)
- C-reactive protein (1)
- C1 inhibitor (1)
- CAD-CAM (1)
- CAD/ CAM crown (1)
- CAD/CAM crown (1)
- CAM (1)
- CAPON (1)
- CCC-2 (1)
- CD16 (1)
- CD34+ cell enumeration (1)
- CD36 (1)
- CD45RA Depletion (1)
- CD47 (1)
- CD62L (1)
- CD8+ T cells (1)
- CDH13 (1)
- CDK2 (1)
- CDK4/6 inhibitors (1)
- CDK9 (1)
- CEST EPI (1)
- CNDAC (1)
- COMP (1)
- COPD (1)
- COVID-19 pandemic (1)
- COVID-19 vaccination (1)
- COVID-19, Primary care (1)
- COVID‐19 (1)
- CRISPR/Cas (1)
- CRPC (1)
- CT (1)
- CT dual-energy computed tomography (1)
- CTLA-4 (1)
- Cabozantinib (1)
- Calcium (1)
- Calcium calmodulin kinase (1)
- Calliphoridae (1)
- Cancer genomics (1)
- Cancer survivors (1)
- Cancer therapy (1)
- Cancer-specific survival (1)
- Cannabis (1)
- Cardiac biomarkers (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardio-oncology (1)
- Cardiotoxicity (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular magnetic resonance (1)
- Carotid injury (1)
- Case report (1)
- Catumaxomab (1)
- Cell death (1)
- Cell division (1)
- Cell-based Assays (1)
- Cement gap (1)
- Ceramides (1)
- Checkpoint Inhibitor (1)
- Chikungunya (1)
- Chimeric Antigen Receptor (CAR) (1)
- Cholinergic (1)
- Chrna7 knockout (1)
- Circadian (1)
- Clinical Global Impression of Change (1)
- Clinical Trials and Observations (1)
- Clinical decision support systems (1)
- Clinical pathway (1)
- Clinical pharmacology (1)
- ClpB (1)
- Cochlear implantation (1)
- Cognitive dysfunction (1)
- Cohort studies (1)
- Colorectal cancer (1)
- Colorimetric blood loss estimation (1)
- Combined surgical therapy (1)
- Combustion (1)
- Complex decongestive therapy (1)
- Complicated stage (1)
- Complications (1)
- Computational models (1)
- Computational neuroscience (1)
- Computational science (1)
- Computed tomography, X-ray (1)
- Computer hardware (1)
- Computer science (1)
- Computer software (1)
- Computer-assisted diagnosis (1)
- Cone-beam computed tomography (1)
- Conometric connection (1)
- Consensus document (1)
- Constipation (1)
- Contingent Negative Variation, CNV (1)
- Continuous Performance Test, CPT (1)
- Continuous renal replacement therapy (1)
- Contrast agent (1)
- Corneal tomography (1)
- Corona virus (1)
- Coronary heart disease (1)
- Costs (1)
- Course (1)
- Covid-19 (1)
- Cre-recombinase (1)
- Crisis (1)
- Critical care (1)
- Cue-P3 (1)
- Culicidae (1)
- Custom-made mouthguard (1)
- Cyclin T1 (1)
- Cystatin C (1)
- DC-NK cell interaction (1)
- DCK (1)
- DNA integrity (1)
- DPPIV (1)
- Data Analysis (1)
- Data processing (1)
- Data reduction (1)
- Daubert criteria (1)
- Dead space (1)
- Decision support (1)
- Deep brain stimulation (1)
- Degradation (1)
- Dengue (1)
- Dentists (1)
- Developmental Biology (1)
- Dexamethasone (1)
- Diagnosis (1)
- Diagnostic algorithm (1)
- Diffusion magnetic resonance imaging (1)
- Diphtheria (1)
- Diptera (1)
- Direct measurement (1)
- Direct oral anticoagulation (1)
- Disease progression (1)
- Diseases (1)
- Dislocations of the knee (1)
- Dizygotic ectopic (1)
- Dopamine (1)
- Dose response (1)
- Droplets (1)
- Drospirenon (1)
- Drug addiction (1)
- Drug resistance (1)
- Drug targets (1)
- Drug therapy (1)
- Dual-energy computed tomography (1)
- Dynamic MRI (1)
- Dysfunctional social assumptions (1)
- D’Amico classification (1)
- EBRT (1)
- ECMO (1)
- EET (1)
- EHL concentrates (1)
- ENIGMA (1)
- EP300 (1)
- EQ5D5L (1)
- EQA scheme (1)
- ER-phagy (1)
- ERAL1 (1)
- ERK inhibitor (1)
- ERK1/2 signaling (1)
- ESBL (1)
- Early setting (1)
- Eccentric fixation (1)
- Ectopic pregnancy (1)
- Effective half-life (1)
- Efficacy (1)
- Efficiency (1)
- Electric stimulation (1)
- Elternurteil (1)
- Emergency room (1)
- Ena/VASP proteins (1)
- Encephalopathy (1)
- Endocrine system and metabolic diseases (1)
- Endocrine therapy (1)
- Endothelial cells (1)
- Endothelial progenitor cells (1)
- Energy (1)
- Engraftment (1)
- Enterobacterales (1)
- Environmental biotechnology (1)
- Environmental sciences (1)
- EpCAM positive tumor (1)
- Ephrin-B2–EphB4 (1)
- Epigenetics (1)
- Epileptische Anfälle (1)
- Epileptischer Anfall (1)
- Epithelialization (1)
- Epsilon (1)
- Estimated glomerular filtration rate (1)
- Event related potentials (1)
- Everolimus (1)
- Evidence-based (1)
- Evidenzbasiert (1)
- Ewing sarcoma (1)
- Ewing-like (1)
- Exercise (1)
- Exercise training (1)
- Exoscope (1)
- Exosomes (1)
- Expansion (1)
- Expectation violation (1)
- External beam radiotherapy (1)
- Extracellular matrix (1)
- Extracellular vesicles (1)
- Exudates and transudates (1)
- FABP (1)
- FAM134 (1)
- FFP3 respirator (1)
- FGFR (1)
- FOXO1 (1)
- FOXO3 (1)
- FXR (1)
- Facial nerve (1)
- Falls (1)
- Feasibility studies (1)
- Fendrr (1)
- Fertility counseling (1)
- Filariasis (1)
- Fluid overload (1)
- Fluorescence (1)
- Forensic entomology (1)
- Forensic experts (1)
- Forensic pathology (1)
- Frontobasal (1)
- Fuchs endothelial dystrophy (1)
- G2A (1)
- GD2 (1)
- GEMs (1)
- GFR (1)
- GIIb/IIIa-receptor (1)
- GMP (1)
- GPCR (1)
- GPR4 (1)
- GTP cyclohydrolase (1)
- Ganglionic (1)
- Gan–Dou–Fu–Mu decoction (GDFMD) (1)
- Gastric motility (1)
- Gastroenterology (1)
- Gender (1)
- Gene expression (1)
- General Practitioner (1)
- Genetic techniques (1)
- Genetics research (1)
- Genome editing (1)
- Gestagen-Monopräparate (1)
- Gezielte Therapie (1)
- Glaucoma (1)
- Gleason Grade Group (1)
- Gleason grade group (1)
- Glioblastoma survival (1)
- Glomerulosclerosis (1)
- Glycolysis (1)
- Grading (1)
- Graft (1)
- Graft quality (1)
- Granulocytes (1)
- Graves’ disease (1)
- Gravimetric method (1)
- Guidance (1)
- Guide profession (1)
- Gut (1)
- H1N1 (1)
- HAE (1)
- HARS2 (1)
- HBV (1)
- HCC (1)
- HCC marker (1)
- HDR-brachytherapy (1)
- HER2 (1)
- HIV (1)
- HIV protease inhibitors (1)
- HL7 FHIR (1)
- HLA antibodies (1)
- HNSCC (1)
- HOLEP (1)
- HOTAIR (1)
- HPO (1)
- HPV-positive OPSCC (1)
- HRCT (1)
- HSC (1)
- HSP (hereditary spastic paraplegia) (1)
- HVPG (1)
- Haematologic diseases (1)
- Haemophilia (1)
- HeLa cells (1)
- Head and neck cancer (1)
- Health care workers (1)
- Health services (1)
- Health surveys (1)
- Healthcare resource utilisation (1)
- Healthcare resource utilization (1)
- Healthy adults (1)
- Healthy men (1)
- Heart (1)
- Heart transplantation (1)
- Heartrate (1)
- Hematologic adverse events (1)
- Hematopoietic stem cell (1)
- Hematotoxicity (1)
- Hepatic stellate cell (1)
- Hepatocellular carcinoma (1)
- Hepatocellular carcinoma (HCC) (1)
- Hereditary angioedema (1)
- Herniated disk (1)
- Heterotopic pregnancy (1)
- Hierarchical drift-diffusion modeling (1)
- High altitude (1)
- High-risk prostate cancer (1)
- Himalayas (1)
- Hip hemiarthroplasty (1)
- Hirschsprung disease (1)
- Hispanic–Latino race/ethnicity (1)
- Histology (1)
- HoLEP (1)
- Hormone receptor positive breast cancer (1)
- Hydromineral (1)
- Hymenoptera venom allergy (1)
- IAP (1)
- ICG (1)
- IFN-β (1)
- IL-17A (1)
- IL-1b (1)
- IL-33 (1)
- INR (1)
- IPSS (1)
- ISR (1)
- IgA deficiency (1)
- Ileostomy (1)
- Ileus (1)
- Image processing (1)
- Immune cells (1)
- Immune checkpoint inhibitors (1)
- Immune complex vasculitis (1)
- Immune paralysis (1)
- Immune status (1)
- Immunodeficiency (1)
- Immunogenetics (1)
- Immunoglobulins (1)
- Immunohistochemistry (1)
- Immunophenotyping (1)
- Immuno‑histochemistry (1)
- Implantable cardioverter-defibrillator (1)
- Implicit Processing (1)
- Implicit Association Test (1)
- In vivo electrophysiology (1)
- Inactivation (1)
- IncX (1)
- Incidence rate (1)
- Incontinence (1)
- Indication for fertility preservation (1)
- Indirect treatment comparison (ITC) (1)
- Indocyanine green (1)
- Indonesia (1)
- Injuries (1)
- Injury (1)
- Intention attribution (1)
- Interleukin-10 (1)
- International normalized ratio (1)
- Internet-based therapy (1)
- Interpretation Bias (1)
- Intervention (1)
- Intervertebral disc displacement (1)
- Interviews (1)
- Intimal-medial thickness (1)
- Intraoperative blood salvage (1)
- Intrinsic resistance (1)
- Intubation (1)
- Isoflurane (1)
- Isothermal amplification (1)
- Ixodes ricinus (1)
- JAK2V617F (1)
- KCCQ (1)
- KCNQ1 (1)
- KLHL11 (1)
- KPS (1)
- Kallikrein inhibitor (1)
- Kappa (1)
- Keap1-Nrf2 (1)
- Ki-67 (1)
- Kindes- und Jugendalter (1)
- Knee surgery (1)
- Kontrazeption (1)
- LARS2 (1)
- LDHB (1)
- LEOSS (1)
- LPS (1)
- LQTS (1)
- LSCC (1)
- LSEC (1)
- LanCL2 (1)
- Lasers (1)
- Lateral flow antigen testing (1)
- Lateral flow immunoassay (1)
- Learning and memory (1)
- Lee type, functional outcome (1)
- Legal medicine (1)
- Leigh syndrome (1)
- Leishmaniasis (1)
- Lemperle (1)
- Leukemia (1)
- Leukocyte depletion filter (1)
- Lipedema (1)
- Liposuction (1)
- Liver Transplantation (1)
- Liver cancer (1)
- Liver fibrosis (1)
- Local therapy (1)
- Long non-coding RNA (1)
- Long non-coding RNAs (1)
- Low grade glioma (1)
- Low-molecular-weight heparin (1)
- Low-virulent infection (1)
- Lung neoplasms (1)
- Lymphocyte subpopulations (1)
- Lymphopenia Mortality (1)
- MDD (1)
- MEIS (1)
- MEK inhibitor (1)
- MLKL (1)
- MN1 (1)
- MRI-negative epilepsy (1)
- MTOR inhibitor (1)
- MTRasym (1)
- MVPA (1)
- MYC (1)
- MYCN amplification (1)
- Macrophage polarization (1)
- Magnetic resonance imaging (1)
- Major depressive disorder (1)
- Malaria (1)
- Malignant meningioma (1)
- Manchester scar scale (1)
- Marginal integrity (1)
- Masking effect (1)
- Mastoiditis (1)
- Matching-adjusted indirect comparison (MAIC) (1)
- Materials science (1)
- Mathematical functions (1)
- Maxillofacial reconstruction (1)
- Maxillofacial trauma (1)
- Medical history (1)
- Meersseman test (1)
- Meningioma (1)
- Mental health and psychiatry (1)
- Mental health therapies (1)
- Metabolic diseases (1)
- Metabolic dysfunction (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Metalloproteinases (1)
- Metastasis-directed therapy (1)
- Metastatic castration-resistant prostate cancer (1)
- Methanol (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Method validation (1)
- Methylphenidate (1)
- MiSpEx-network (1)
- Micro computed tomography (1)
- MicroRNAs (1)
- Microbiology and Infectious Disease (1)
- Microgap (1)
- Microwave ablation (1)
- Minimal invasive dentistry (1)
- Mitochondrial ROS (1)
- Mitochondrial dysfunction (1)
- Mitosis (1)
- Molecular Biology (1)
- Molecular diagnostics (1)
- Molecular neuroscience (1)
- Monoclonal antibody (mAb) (1)
- Monocytes (1)
- Mosquito (1)
- Motivation (1)
- Mountain (1)
- Multianalyte detection (1)
- Multidrug-resistant organisms (1)
- Multiligament instability (1)
- Multivariate analysis (1)
- Musculoskeletal abnormalities (1)
- Musculoskeletal problems (1)
- Musculoskeletal system (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myeloid Neoplasia (1)
- Myiasis (1)
- Myocardial infarction (1)
- Myocardial remodeling (1)
- N471D strumpellin knock-in mice (1)
- N501Y (1)
- NAFLD (1)
- NASH (1)
- NET (1)
- NFkB (1)
- NK cell subsets (1)
- NK-92 (1)
- NO (1)
- NOS-I (1)
- NOS1AP (1)
- NSBB (1)
- NURF (1)
- Natural killer cells (1)
- Necroptosis (1)
- Necrotizing enterocolitis (1)
- Negligence (1)
- Nephrectomy (1)
- Neural stem cells (1)
- Neurodegeneration (1)
- Neuroepithelial (1)
- Neuroepithelial tumor (1)
- Neurofeedback (1)
- Neurofilament light chain (1)
- Neuroligins (1)
- Neurooncology (1)
- Neuropilin (1)
- Neurotoxicity (1)
- Neurovascular damage (1)
- Next-generation sequencing (1)
- NfL (1)
- Niche (1)
- Nicotine (1)
- Nitric oxide (1)
- Nonaerosolizing treatment (1)
- Nontuberculous mycobacteria (1)
- Noradrenergic (1)
- Norepinephrine (1)
- Nox4 (1)
- Nrf-2 (1)
- Nrf2 (1)
- Nutrition (1)
- OA (1)
- OGR1 (1)
- OHIP-G14 (1)
- OHRQoL (1)
- ORP (1)
- OSCE (1)
- OXA-48 (1)
- OXA-484 (1)
- OXPHOS (1)
- Obstetrics and gynecology (1)
- Occlusion treatment (1)
- Occupational health (1)
- Older patient (1)
- Olfactory groove meningioma (1)
- Olfactory system (1)
- Oligodendroglioma (1)
- Oligometastatic (1)
- Omega lipids (1)
- Oncogenes (1)
- Oncology (1)
- Online Survey (1)
- Opinion (1)
- Opioids (1)
- Opportunistic infections (1)
- Oral food challenge (1)
- Oral immunotherapy (OIT) (1)
- Oral therapy (1)
- Orbital fracture (1)
- Organ failure (1)
- Organ injury (1)
- Orthodontic tooth movement (1)
- Osteoporotic fractures (1)
- Otorhinolaryngological (1)
- Outcomes (1)
- Outcomes research (1)
- Outpatients (1)
- Overweight (1)
- Oxidative phosphorylation (1)
- P2X7 receptor (1)
- PAC-1 (1)
- PAD-test (1)
- PAPR (1)
- PATZ1 (1)
- PBSC (1)
- PBX (1)
- PD-1 (1)
- PD-L1 (1)
- PLAGL1 (1)
- PMA (1)
- PML (1)
- PMMA (1)
- POCT (1)
- POR (1)
- PPAR-γ (1)
- PRF (1)
- PRNT (1)
- PRRT (1)
- PSA (1)
- PTEN inducible kinase 1 (1)
- PTM (1)
- Pacemaker (1)
- Pain (1)
- Pain management (1)
- Palacos reaction (1)
- Pandemie (1)
- Parenteral nutrition (1)
- Parkinson's disease (1)
- Parkinson’s disease (1)
- Particulates (1)
- Pathogens (1)
- Pathology (1)
- Pathophysiology (1)
- Patient manikins (1)
- Patient perspective (1)
- Patient preference (1)
- Patterns of care (1)
- Pediatric oncology (1)
- Pediatric stem cell transplantation (1)
- Pediatric surgery (1)
- Per1−/−-mice (1)
- Peri-implant disease (1)
- Peritoneal macrophages (1)
- Peritumoural oedema (1)
- Peri‑implantitis (1)
- Persistence SARS-CoV-2 antibodies (1)
- Personal protective equipment (1)
- Personalisierte translationale Therapie (1)
- Personalized medicine (1)
- Phagocytosis (1)
- Phantoms (imaging) (1)
- Pharmacokinetics (1)
- Pharmacology (1)
- Pharmacotherapy (1)
- Phase 3 (1)
- Phase 3 trial (1)
- Phenylketonuria (PKU) (1)
- Physical self-perception (1)
- Play (1)
- Pleasure (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Podospora anserina (1)
- Point of care (1)
- Point-of-care wound diagnostics (1)
- Poly-Pore (1)
- Polypharmacy (1)
- Population dynamics (1)
- Portal veins (1)
- Post mortem examination (1)
- Post-cesarean (1)
- Post-offence drinking (1)
- Post-thaw recovery (1)
- Post-traumatic stress disorder (1)
- Postmortem (1)
- Postmortem interval (1)
- Posture analysis (1)
- Potassium iodide (1)
- Powered air-purifying respirator (1)
- Pre-analytics (1)
- Preclinical research (1)
- Prediction of locoregional recurrence (1)
- Predictive coding (1)
- Predictive markers (1)
- Predictive model (1)
- Prevention (1)
- Preventive medicine (1)
- Primary care (1)
- Primary health care (1)
- Primary molars (1)
- Primärversorgung (1)
- Principal component analysis (1)
- Prisoners (1)
- Prisons (1)
- Probability density (1)
- Probability distribution (1)
- Proficiency testing (1)
- Prognostic markers (1)
- Prognostic models (1)
- Protease inhibitor therapy (1)
- Proximal (1)
- Pseudomonas aeruginosa (1)
- Pseudophakia (1)
- Psoriasis (1)
- Psoriatic arthritis (1)
- Psychiatric disorders (1)
- Psychiatry (1)
- Psychology (1)
- Pyogenic spondylodiscitis (1)
- Python (1)
- Qualitative study (1)
- Quality control (1)
- RARP (1)
- RAS pathway (1)
- RCT (1)
- RET (1)
- RGAG1 (1)
- RMS (1)
- RNA (1)
- RNA sequencing (1)
- RNA therapeutics (1)
- RNA therapy (1)
- RNA-binding protein (1)
- RNA-sequencing (1)
- RNAP II (1)
- RND (1)
- RNF4 (1)
- ROC analyses (1)
- ROC-Analysen (1)
- ROS1 (1)
- RT-PCR-detection (1)
- Race (1)
- Radiation Oncology (1)
- Radiation necrosis (1)
- Radical prostatectomy (1)
- Radiochemotherapy (1)
- Radioiodine therapy (1)
- Radioiodine uptake test (1)
- Radiology (1)
- Radiomics (1)
- Radiosurgery (1)
- Ramucirumab (1)
- Randomisation (1)
- Randomized Controlled Trial (1)
- Randomized controlled trial (1)
- Reactive oxygen species (1)
- Ready-made mouthguard (1)
- Real-time MRI (1)
- Real-time polymerase chain reaction (PCR) tests (1)
- Rectal cancer (1)
- Redoxin (1)
- Refractive changes (1)
- Region (1)
- Registry (1)
- Renal cell carcinoma (1)
- Rescue medication (1)
- Resection (1)
- Residual myometrial thickness (1)
- Respiratory distress syndrome (1)
- Respiratory infections (1)
- Response control (1)
- Restenosis (1)
- Resting-state (1)
- Retrospective study (1)
- Reward (1)
- Rhabdomyoma (1)
- Rho-kinase (1)
- Ridge preservation (1)
- Riftia pachyptila (1)
- Risk factor (1)
- Risk stratification (1)
- Roussel Uclaf Causality Assess- ment Method (RUCAM) (1)
- S1P lyase (1)
- S63845 (1)
- SAH (1)
- SAMHD1 (1)
- SARS CoV 2 (1)
- SARS-CoV-2 testing (1)
- SARS-CoV‑2 (1)
- SCCHN (1)
- SCD14 (1)
- SEC-ICP-DRC-MS (1)
- SEER (1)
- SELEX (1)
- SF-36 (1)
- SGPL1 (1)
- SGPL1 knockout cell line (1)
- SH-SY5Y neuroblastoma cells (1)
- SIRPalpha (1)
- SIRT1 (1)
- SKALE score (1)
- SLC6a3 (1)
- SLC7A11 (1)
- SPG8 (1)
- SUMO (1)
- Safety (1)
- Salivary gland cancer (1)
- Salivary gland carcinoma (1)
- Sandfly (1)
- Sapacitabine (1)
- Sarcoma (1)
- Satisfaction (1)
- Scheimpflug imaging (1)
- Schizophrenia (1)
- Sclerotic glomeruli (1)
- Screeningfragebogen (1)
- Seasonal variation (1)
- Sedation (1)
- Sedatives (1)
- Seizures (1)
- Self-esteem (1)
- Sequencing (1)
- Short bowel syndrome (1)
- Side effect (1)
- Silver diamine fluoride (1)
- Simulated patients (1)
- Simulation training (1)
- Single-cell RNA sequencing (1)
- Skeletal health (1)
- Skull base (1)
- Slow Cortical Potentials, SCP (1)
- Smac mimetics (1)
- Smoking habits (1)
- Social Phobia (1)
- Social cognition (1)
- Social decision-making (1)
- Social neuroscience (1)
- Sociodemographic characteristics (1)
- Socket healing (1)
- Socket preservation (1)
- Soft tissue healing (1)
- Software (1)
- Solar insolation (1)
- Sonication (1)
- Sonography (1)
- Spinal fractures (1)
- Spinal surgery (1)
- Sport (1)
- Stability (1)
- Standard value (1)
- Standardization (1)
- Static MRI (1)
- Stem cell dose (1)
- Stem cell enumeration (1)
- Stereotactic ablative body radiotherapy (1)
- Stimulant (1)
- Sting challenge (1)
- Structured written feedback (1)
- Subependymal giant cell astrocytoma (1)
- Sudden Cardiac Death (SCD) (1)
- Suicidality (1)
- Sunlight (1)
- Superficial vein thrombosis (1)
- Supratentorial (1)
- Surgical blood loss (1)
- Surgical site infection (1)
- Sustained attention (1)
- Symmetrical blocked occlusion (1)
- Synaptic organizer (1)
- Synaptic transmission (1)
- Synaptosomal preparation (1)
- Syndecan-1 (1)
- Synthetic biology (1)
- Syrian hamster (1)
- Systematic review (1)
- T-cell development (1)
- T-cell receptor (TCR) (1)
- T-cells (1)
- TACE (1)
- TAM (1)
- TAVI (1)
- TDAG8 (1)
- TGF-β1 (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TIPS (1)
- TLR4 (1)
- TME (1)
- TMT (1)
- TRAIL (1)
- TRP2 (1)
- TRPM8 (1)
- TRPV4 (1)
- TSP-4 (1)
- TTFields (1)
- TURP (1)
- TWNK (1)
- Taekwondoka (1)
- Tailored therapy (1)
- Tar (1)
- Targeted therapy (1)
- Telemedicine (1)
- Temozolomide (1)
- Tempo-parietal junction (1)
- Temporomandibular joint (1)
- Temporomandibular joint dysfunction (1)
- Tetanus (1)
- Tetrahydrobiopterin (1)
- Theft (1)
- Therapeutic anticoagulation (1)
- Thermogenesis (1)
- Thorax (1)
- Thyroid (1)
- Time of death (1)
- Time trend (1)
- Tobacco (1)
- Tomography (1)
- Tooth segmentation (1)
- Traditional Chinese Medicine (TCM) (1)
- Traditional Indian Medicine (1)
- Trajectories (1)
- Transcranial direct current stimulation (1)
- Transcription (1)
- Transcriptomics (1)
- Transdifferentiation (1)
- Transfusion (1)
- Translation (1)
- Translational research (1)
- Transplant logistics (1)
- Transplantation Centers (1)
- Travel times (1)
- Trisomy 21 (1)
- Troponin (1)
- Tuberous sclerosis complex (1)
- Tumor cell (1)
- Type three hypersensitivity (1)
- Tyrosine kinase inhibitor (TKI) (1)
- Tyrosinemia (1)
- Ulixertinib (1)
- Understanding (1)
- Undiagnosed patients (1)
- Upper airway infection (1)
- Upper body posture (1)
- Urethral cancer (1)
- Uterus (1)
- VEGF receptor 2 internalization and signaling (1)
- VEGF receptors (1)
- VRE (1)
- Vaccine (1)
- Vagus nerve (1)
- Vagus nerve stimulation (1)
- Vascular endothelial growth factor (VEGF) (1)
- Ventilators (1)
- Video rasterstereography (1)
- Virtual noncalcium reconstructions (1)
- Virus trapping (1)
- Visual quality (1)
- WASH complex subunit 5 (1)
- WIPI2 (1)
- WIPI2b (1)
- Weight distribution (1)
- White blood cells (1)
- White matter hyperintensity (1)
- Wilson disease (WD) (1)
- Wnt (1)
- Working memory capacity (1)
- Wound healing (1)
- Wounds and injuries (1)
- X-ray computed (1)
- Yoga (1)
- Zika Virus (1)
- Zika fever (1)
- Zymosan-induced peritonitis (1)
- ablation (1)
- abscisic acid (1)
- abscopal effect (1)
- acetaminophen (1)
- acne inversa (1)
- acoustic radiation force impulse (1)
- action (1)
- activated factor XIII (1)
- acute decompensation (1)
- acute pain (1)
- acute stroke care (1)
- adaptation (1)
- adenosine (1)
- adhesion (1)
- adipocytes (1)
- adipose-derived stromal/stem cells (1)
- adolescence (1)
- adolescent (1)
- adult (1)
- advanced melanoma (1)
- adversity (1)
- age (1)
- aged (1)
- agent-based models (1)
- agility (1)
- agreeableness (1)
- air abrasive (1)
- allogeneic hematological stem cell transplantation (1)
- allogeneic stem cell transplant (1)
- allostasis (1)
- alpha power (1)
- alpha-synuclein (1)
- alpha7 nicotinic acetylcholine receptor (1)
- amide proton transfer (1)
- amyotrophic lateral sclerosis (1)
- aneurysm (1)
- animal model (1)
- anorectal malformation (1)
- anti-neural autoantibodies (1)
- antiadhesive composites (1)
- antibacterial composites (1)
- antibiotic prophylactic therapy (1)
- antibiotic prophylaxis (1)
- antibiotics (1)
- anticipation (1)
- anticoagulation (1)
- antiepileptic drug (1)
- antihelix shaping (1)
- antimicrobial stewardship (1)
- antiviral signaling (1)
- anxiety (1)
- anxiety disorders (1)
- aortic root replacement (1)
- aortic valve repair (1)
- aortic valve stenosis (1)
- aortic valve-sparing (1)
- aphrodisin (1)
- apical constriction (1)
- apical polarity (1)
- aptamer (1)
- aptamer modeling (1)
- arterial stiffness (1)
- articular cartilage (1)
- artifacts (1)
- artificial feeding (1)
- artificial intelligence (1)
- artificial intelligence (AI) (1)
- assembly (1)
- assembly factor (1)
- asthma (1)
- asymptomatic temporal encephaloceles (1)
- at-risk mental state (1)
- ataxia (1)
- atopic dermatitis (1)
- atrial fibrillation (1)
- attachment (1)
- attention (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- auditory (1)
- auditory cortex (1)
- augmentation (1)
- autism (1)
- autoantibodies (1)
- autobiographical memories (1)
- autogenous tooth roots (1)
- autoimmune encephalitis (1)
- autoimmune-mediated psychosis (1)
- automatic scene classification (1)
- autophagy inhibition (1)
- azacitidine (1)
- bacteremia (1)
- bacteria (1)
- bacterial leakage (1)
- bacterial viability (1)
- bacteriophages (1)
- ball (1)
- basilar artery occlusion (BAO) (1)
- bats (1)
- behavioral inhibition (1)
- behavioural rhythms (1)
- benfooxythiamine (1)
- best medical treatment (1)
- beta-band activity (1)
- beta-lactamases (1)
- bibliometric analysis (1)
- bilateral (1)
- bile (1)
- bile acids (1)
- binocular vision (1)
- biochemical relapse free survival (1)
- biologization (1)
- bladder neck stenosis (1)
- blood cell mutations (1)
- blood coagulation (1)
- blood concentrates (1)
- blood culture (1)
- blood transfusion (1)
- blood-brain barrier (1)
- bloodstream infections (1)
- body plethysmography (1)
- bone (1)
- bone augmentation (1)
- bone barrow (1)
- bone regeneration (1)
- bone-regeneration (1)
- bowel dysfunction (1)
- brachytherapy (1)
- brain disorders (1)
- brain imaging (1)
- brain infection (1)
- brain metastases (1)
- cAMP (1)
- cGMP (1)
- calretinin (1)
- cancer cell metabolism (1)
- cancer immunotherapy (1)
- cancer metastases (1)
- cancer specific survival (1)
- cancer surveillance (1)
- cancer therapy (1)
- cancer treatment (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- cannabinoid receptors (1)
- carbapenem resistance (1)
- carbapenemases (1)
- cardiac differentiation (1)
- cardiac magnetic resonance (1)
- cardiac regeneration (1)
- cardiac reprogramming (1)
- cardiocerebral resuscitation (1)
- cardiomyocyte apoptosis (1)
- cardiomyocyte proliferation (1)
- cardiomyocytes (1)
- cardiopulmonary resuscitation (1)
- cardiovascular disease (1)
- caregivers (1)
- cartilage (1)
- castration resistance (1)
- cell barrier integrity (1)
- cell culture (1)
- cell differentiation (1)
- cell heterogeneity (1)
- cell lines (1)
- cell proliferation regulating inhibitor of protein phosphatase 2A (1)
- cellular therapies (1)
- central nervous system (1)
- central spasticity (1)
- ceramides (1)
- cerebral imaging (1)
- cerebral ischemia (1)
- cerebral metastasis (1)
- cerebral palsy (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- cervical cancer (1)
- cetuximab (1)
- chaperone-mediated autophagy (1)
- chemokines (1)
- chemoradiotherapy (1)
- childhood cancer (1)
- children and adolescents (1)
- cholesterol (1)
- cholinergic system (1)
- chronic (1)
- chronic granulomatous disease (1)
- chronic hepatitis C (1)
- chronic inflammation (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- clindamycin (1)
- clinical decision-making (1)
- clinical high at-risk mental state (1)
- clinical isolates (1)
- clinical research (1)
- clinical stage (1)
- clinical teaching (1)
- clinically important restrictions and symptoms (1)
- clonal haematopoiesis (1)
- cluster analysis (1)
- cluttering (1)
- co-infection (1)
- cochlear implant (1)
- cochlear implants (1)
- collagen (1)
- collagen membranes (1)
- collective cell migration (1)
- colorectal cancer (1)
- combined modality therapy (1)
- comorbidities (1)
- complementary medicine (1)
- complete response (1)
- complex systems (1)
- compound screen (1)
- computational knowledge-discovery (1)
- computer-assisted (1)
- concordance (1)
- confinement (1)
- congenital diaphragmatic hernia (1)
- congenital disorders of autophagy (1)
- conical coupling (1)
- conometric connection (1)
- consensus (1)
- conservative dentistry (1)
- constipation (1)
- contraception (1)
- control of menstrual bleeding (1)
- convulsive seizures (1)
- coping (1)
- core expression (1)
- corona virus (1)
- coronally advanced flap (1)
- corticosteroids (1)
- cost-effective (1)
- criteria (1)
- critical-size defect (1)
- critically ill patients (1)
- cross-linking (1)
- curcumin (1)
- cyclic nucleotide analogues (1)
- cyclic nucleotide binding proteins (1)
- cycling (1)
- cyclooxygenase-2 (1)
- cytochrome P450 enzymes (1)
- cytochrome P450 reductase (1)
- cytokines (1)
- cytotoxic T lymphocyte (1)
- dance teacher (1)
- data quality (1)
- data repositories (1)
- data sharing (1)
- death rates (1)
- decompressive craniectomy (1)
- default mode network (1)
- degradation (1)
- delayed diagnosis (1)
- delivery mode (1)
- delta (1)
- dendrite morphogenesis (1)
- dendritic cells (1)
- dengue vector (1)
- dental assistant (1)
- dental education (1)
- dental implant (1)
- dental school (1)
- dental treatment concept (1)
- dentist (1)
- dentist’s chair design (1)
- depth perception (1)
- desensitization (1)
- development (1)
- diabetes complication (1)
- diabetic nephropathy (1)
- diagnosis (1)
- diet (1)
- diffuse marrow involvement (1)
- digital medicine (1)
- digital one-piece casting (1)
- digital pressing technology (1)
- digital workflow (1)
- dihydrocannabidiol (1)
- diphtheria toxin (1)
- direct-acting antiviral (DAA) treatment (1)
- discontinuation (1)
- disease progression (1)
- dislocation (1)
- disordered iron metabolism (1)
- dobutamine stress (1)
- docetaxel (DX) resistance (1)
- dopamine transporter (1)
- dorsal attention network (1)
- double immune checkpoint inhibition (1)
- downgrading (1)
- doxycycline (1)
- drinking (1)
- drospirenone (1)
- drug (1)
- drug–drug interactions (1)
- drug–gene interactions (1)
- drug–g–gene interactions (1)
- dual-energy (1)
- dynamic causal modeling (1)
- dynamic system (1)
- early onset (1)
- early-onset prostate cancer (1)
- echo planar imaging (1)
- edentulous (1)
- efferocytosis (1)
- efflux pump (1)
- egg sampling (1)
- elastin (1)
- electrical coupling (1)
- electroanatomical mapping (1)
- electrode design (1)
- electroencephalography (1)
- electroencephalography (EEG) (1)
- electrolytic cleaning (1)
- electron transfer (1)
- element speciation (1)
- emergency care (1)
- emicizumab (1)
- endodontic curriculum (1)
- endodontic education (1)
- endodontics (1)
- endothelial dysfunction (1)
- endourology (1)
- endovascular treatment (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- enzyme activity assay (1)
- epidermal growth factor receptor (1)
- epilepsy surgery (1)
- erastin (1)
- erythropoiesis (1)
- essential thrombocythemia (ET) (1)
- ethanol (1)
- everolimus (1)
- executive functions (1)
- exercise (1)
- expert witness statement (1)
- extraskeletal (1)
- eye movements (1)
- fMLP (1)
- factor XIII (1)
- faecal microbiota transfer (1)
- fall (1)
- famotidine (1)
- fasting insulin (1)
- fat grafting (1)
- fatty acid synthesis (1)
- fecal incontinence (1)
- fecal microbiota transfer (1)
- females (1)
- fenfluramine (1)
- ferric carboxymaltose (1)
- ferric derisomaltose (1)
- ferroportin (1)
- ferroptosis (1)
- ferumoxytol (1)
- fibrinolysis (1)
- fibrosis (1)
- first-time shoulder dislocation (1)
- flow cytometry (1)
- fondaparinux (1)
- fracture strength (1)
- fracture strength equation (1)
- frontotemporal dementia (1)
- full-arch restoration (1)
- function (1)
- functional connectome acute (1)
- functional magnetic resonance imaging (1)
- functional outcome (1)
- fungal sugar (1)
- fusion (1)
- fusion kinase (1)
- gait symmetry (1)
- gargle lavage (1)
- gastrointestinal stromal tumours (1)
- gender (1)
- genetic diversity (1)
- genetic variants (1)
- genetically caused iron imbalance (1)
- genotype G (1)
- geriatrics (1)
- gingival recession therapy (1)
- glioma (1)
- glioma microenvironment (1)
- global health (1)
- glucose-6-phosphate dehydrogenase (1)
- glucosylceramides (1)
- glycoproteins (1)
- gp100 (1)
- graft-vs-host disease (1)
- granule polarization (1)
- graphic 3D models (1)
- great height (1)
- grisel syndrome (1)
- growth (1)
- growth inhibition (1)
- guided bone regeneration (1)
- guideline (1)
- haNK (1)
- haemophilia (1)
- harmonization (1)
- hatching (1)
- head and neck neoplasms (1)
- health database (1)
- health information interoperability (1)
- health-relatedquality of life (1)
- healthy control (1)
- hematotoxicity (1)
- hemorrhage (1)
- hepatitis C virus (1)
- herb-induced liver injury (HILI) (1)
- heterogeneity (1)
- high risk (1)
- high-altitude adaptation (1)
- high-altitude pulmonary hypertension (1)
- high-fat-diet (1)
- high-risk (1)
- high-risk neuroblastoma (1)
- hip osteoarthritis (hip OA) (1)
- hippocampus (1)
- histamine (1)
- histopathological growth pattern (1)
- homeodomain protein (1)
- homeostasis (1)
- hospital admission (1)
- host-microbe interaction (1)
- human allogeneic hematopoietic cell transplantation (1)
- human behaviour (1)
- human factors (1)
- human intestinal microbiota (1)
- human olfaction (1)
- human subjects (1)
- humans (1)
- hybrid materials (1)
- hybrid production (1)
- hydrogen peroxide (1)
- hypersensitivity (1)
- hypobaric hypoxia (1)
- hypophosphatemia (1)
- hypoxia inducible factor 1 alpha (1)
- iCBT (1)
- idiosyncratic drug-induced liver injury (DILI) (1)
- image-guided tissue acquisition (1)
- imaging genetics (1)
- imaging protocol (1)
- immobilization in external rotation and abduction (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune escape (1)
- immune host defense (1)
- immune infiltration (1)
- immunohistochemistry (1)
- immunological risk (1)
- impulsivity (1)
- incidence (1)
- incontinence (1)
- induction chemotherapy (1)
- induction regimen (1)
- induction therapy (1)
- inertial motion units (1)
- infection (1)
- infection control (1)
- infection precaution (1)
- infections (1)
- infectivity (1)
- inflammasome (1)
- inflammatory bowel disease (1)
- inflammatory reaction (1)
- informal care (1)
- inherited (1)
- inhibitor (1)
- inhibitory control (1)
- injury pattern (1)
- injury prevention (1)
- inosine (1)
- insurance data (1)
- integrate-and-fire (1)
- integrative medicine (1)
- integrative neuromotor training (1)
- intellectual disability (1)
- intensive care admission and mortality (1)
- interim positron emissiontomography (1)
- interleukin-22 (1)
- international transport (1)
- interstitial multicatheter brachytherapy (1)
- intestinal iron loss (1)
- intestinal manipulation (1)
- intracellular (1)
- intracerebral hemorrhage (ICH) (1)
- intracranial hemorrhage (1)
- intranasal administration (1)
- intraoperatively molded (1)
- intravenous iron (1)
- intravenous iron therapy (1)
- intrinsic and innate immune response (1)
- invasive fungal disease (1)
- inverse spacer (1)
- inverse stage migration (1)
- iron deficiency anemia (1)
- iron isomaltoside (1)
- iron-trafficking (1)
- irritable bowel syndrome (1)
- jejunoileal atresia (1)
- joint innervation (1)
- joint load (1)
- juvenile myelomonocytic leukemia (1)
- kidney transplantation (1)
- kinematic analysis (1)
- landrace pigs (1)
- language impairment (1)
- lasso regression (1)
- layer-specificity (1)
- learning and memory (1)
- left atrial appendage occlusion (1)
- legislation (1)
- leisure-time activity (1)
- lenalidomide (1)
- leptin receptor-deficient mouse (1)
- leucocytes (1)
- leukemia (1)
- leukocytes (1)
- leukodystrophy (1)
- life table (1)
- life-expectancy (1)
- lifestyle intervention (1)
- light irradiation (1)
- limitations (1)
- lipids (1)
- lipofilling (1)
- lipofuscin (1)
- live-cell imaging (1)
- live/dead staining (1)
- liver X receptor (1)
- liver damage (1)
- liver metastasis (1)
- liver steatosis (1)
- liver stiffness (1)
- liver volume (1)
- local drug delivery (1)
- local preemptive analgesia (1)
- local recurrence (1)
- local treatment (1)
- location (1)
- locator (1)
- logistic models (1)
- long non-coding RNA (1)
- long term (1)
- long-term outcome (1)
- long-term success (1)
- loss of B-cell phenotype (1)
- loss-of-function (1)
- low molecular weight heparin (1)
- low risk (1)
- low-back-pain (1)
- low-carbohydrate (1)
- low-dose irradiation (1)
- low-glycaemic meal replacement (1)
- lower leg fracture (1)
- lung development (1)
- lung function (1)
- lungs (1)
- lymph node metastases (1)
- mRNA stability (1)
- mRNA1273 (1)
- mTOR (1)
- mTOR inhibitor (1)
- machine-learning (1)
- magnetoencephalography (1)
- male (1)
- malignancy (1)
- mammary carcinoma (1)
- manganese (1)
- marginal fit (1)
- marked lymph node (1)
- mass spectrometry (1)
- mathematical analysis (1)
- mathematical modeling (1)
- mechanotransduction (1)
- medical risk factors (1)
- medulloblastoma (1)
- melanoma (1)
- membrane-less organelles (1)
- membranous urethral stricture (1)
- meningioma (1)
- mental health (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal/stem cells (1)
- mesial temporal lobe epilepsy (1)
- meta-analysis (1)
- metabolic liver disease (1)
- metabolic rewiring (1)
- metabolism (1)
- metabolomics (1)
- metastatic renal cell carcinoma (1)
- mice (1)
- michael acceptor (1)
- microbiome (1)
- microdissection (1)
- microsurgery (1)
- microvesicles (1)
- mild cognitive impairment (1)
- minimally invasive therapy (1)
- minocycline (1)
- mitochondrial disease (1)
- mitochondrial respiration (1)
- mitral regurgitation (1)
- mitral valve surgery (1)
- mold (1)
- molecular marker (1)
- molecular neuroscience (1)
- molecular surveillance (1)
- monitoring (1)
- monoacylglycerol lipase (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- monocytes (1)
- monotherapy (1)
- mood (1)
- morbidity (1)
- motor functions (1)
- motor-control-exercise (1)
- mouse (1)
- mouse models (1)
- mouse tumor model (1)
- mucormycetes (1)
- multi-material 3D printing (1)
- multi-scale models (1)
- multicenter study (1)
- multicentre study (1)
- multidisciplinary-therapy (1)
- multimorbidity (1)
- multiple myeloma (1)
- multisensory integration (1)
- multislice imaging (1)
- multivoxel pattern analysis (1)
- musculoskeletal disorders (1)
- musculoskeletal repair (1)
- musculoskeletal system (1)
- mutation (1)
- mutism (1)
- myeloproliferative neoplasms (MPN) (1)
- myocardial efficiency (1)
- myocardial fibrosis (1)
- myocardial ischaemia (1)
- myocardial power (1)
- nNOS (1)
- nasal swab (1)
- natural selection (1)
- natural sounds (1)
- necroptosis (1)
- neoadjuvant therapy (1)
- neonate (1)
- neovascularization (1)
- neural correlates (1)
- neural oscillations (1)
- neurodegeneration (1)
- neurodevelopment (1)
- neurodevelopmental disorde (1)
- neuroendocrine tumor (1)
- neuroethology (1)
- neurogenic bowel (1)
- neuroimaging (1)
- neurological manifestations (1)
- neurology (1)
- neuropeptide (1)
- neuropeptides (1)
- neuroprotection (1)
- neurotransmitter (1)
- neutralization (1)
- neutralizing antibody (1)
- next-generation sequencing (1)
- nitric oxide (1)
- nitroalkene (1)
- nitroglycerin (1)
- nociception (1)
- nodular lymphocyte-predominant Hodgkin lymphoma (1)
- nomogram (1)
- non-aneurysmal (1)
- non-aneurysmal SAH (1)
- non-coding RNA (1)
- non-contact injuries (1)
- non-perimesencephalic (1)
- non-small cell lung cancer (1)
- nontraumatic atlantoaxial rotatory subluxation (1)
- nucleic acid amplification test (1)
- nucleic acid docking (1)
- nucleic acid lateral flow immunoassay (1)
- nucleolus (1)
- nucleoredoxin (1)
- nutrition - clinical (1)
- nymphs (1)
- obesity (1)
- observational study (1)
- olfaction (1)
- oluble epoxide hydrolase (1)
- oncogenesis (1)
- oncogenic RAS (1)
- oncological exercise therapy (1)
- online intervention (1)
- online research (1)
- online survey (1)
- open field behavior (1)
- open science (1)
- open skill exercise (1)
- operating microscope (1)
- oral health (1)
- oral health burden (1)
- oral progestins (1)
- orale Gestagene (1)
- ordinary differential equations (ODE) (1)
- organ preservation (1)
- organic nitrates (1)
- organotypic culture (1)
- other cause mortality (1)
- otoplasty (1)
- outcomes (1)
- ovarian cancer (1)
- overdenture (1)
- overtreatment (1)
- overweight (1)
- oviposition (1)
- oviposition substrate (1)
- ovitrap (1)
- oxaliplatin (1)
- oxythiamine (1)
- p-eIF2α (1)
- p21Cip1/CDKN1A (1)
- p53 pathway (1)
- pH (1)
- pad-test (1)
- pain intensity (1)
- paired samples (1)
- palliative care (1)
- palliative care services (1)
- pancreatic ductal adenocarcinoma (1)
- pannexin-1 (1)
- paper-based detection (1)
- paracrine signaling (1)
- parent rating (1)
- pathogen (1)
- patient preferences (1)
- patient safety (1)
- patient–doctor relationship (1)
- pediatric solid tumors (1)
- pelvic trauma (1)
- penile cancer (1)
- pentaerythritol tetranitrate (1)
- peptide receptor radionuclide therapy (1)
- perforant path transection (1)
- peri-implant disease (1)
- peri-implant diseases (1)
- peri-implantitis (1)
- peri-implantitis treatment (1)
- periimplantitis (1)
- perimesencephalic (1)
- periodontal diseases (1)
- periodontal treatment (1)
- peripheral blood stem cell collection (1)
- peritoneal macrophages (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- peroxisome proliferator-activated receptor (1)
- persistent periodontal pockets (1)
- personalized (1)
- phagocytes (1)
- phagocytosis (1)
- pharmacodynamics (1)
- pharmacoepigenetics (1)
- pharmacogenetics (1)
- pharmacological data science (1)
- pharmacological plasticity (1)
- phase IV (1)
- phase separation (1)
- phenoconversion (1)
- pheromone (1)
- phosphoproteomics (1)
- photodynamic therapy (1)
- physical activity (1)
- physiotherapy (1)
- pitch (1)
- plasmid (1)
- platelet hyperactivity (1)
- platelet substitution (1)
- platelet-rich-fibrin (1)
- point-of-care diagnostics (1)
- polo-like kinases (1)
- polyQ (1)
- polycythemia vera (PV) (1)
- polymer infiltrated ceramic network (1)
- polymeric micelle (1)
- polypept(o)ide (1)
- polypharmacy (1)
- polytrauma (1)
- polyunsaturated fatty acid (1)
- portal pressure (1)
- positron-emissions-tomography (1)
- post-transcriptional regulation (1)
- posterior circulation (1)
- postinfectious bronchiolitis obliterans (1)
- postoperative pain (1)
- potassium channel (1)
- preclinical (1)
- prediabetes and type 2 diabetes (1)
- prediction (1)
- predictive (1)
- predictive coding (1)
- predictor (1)
- preeclampsia (1)
- prehabilitation (1)
- prepontine (1)
- preventive strategies (1)
- primary biliary cholangitis (1)
- primary immunodeficiency (1)
- primary myelofibrosis (PMF) (1)
- prion-like (1)
- production (1)
- progestin mono-preparation (1)
- prognostic (1)
- prognostic scores (1)
- progranulin (1)
- promyelocytic leukemia nuclear bodies (1)
- prostate cancer (PCa) (1)
- prostate neoplasm (1)
- proteasome (1)
- protein aggregation (1)
- protein complexes (1)
- protein evolution (1)
- protein folding (1)
- protein phosphorylation (1)
- protein-rich (1)
- protein–protein interaction (1)
- proteoglycan (1)
- proteomics (1)
- proton pumping (1)
- proton-sensing GPCR (1)
- protruding ear (1)
- pseudomonas aeruginosa (1)
- psoriasis (1)
- psychiatric disorders (1)
- psychogenic non-epileptic seizures (1)
- psychosocial factors (1)
- public health (1)
- publication output (1)
- pulsed SILAC (1)
- quantitative MRI (1)
- quantitative RUCAM (1)
- quantitative magnetic resonance imaging (1)
- quiescence (1)
- radiation (1)
- radiation-induced (1)
- radio sensitivity (1)
- radioimmunotherapy (1)
- radiomics (1)
- randomized (1)
- randomized controlled trial (1)
- rare disease (1)
- rare mendelian disorders (1)
- rat calvaria defect (1)
- re-irradiation (1)
- reactive coordination (1)
- reactive oxygen species (1)
- real-world (1)
- recall (1)
- recombinase polymerase amplification (1)
- recovery (1)
- recurrent urinary tract infections (1)
- red cells (1)
- reduced kidney function (1)
- reduction potential (1)
- regenerative therapy (1)
- relapsing–remitting multiple sclerosis (1)
- remodeling (1)
- renal cell carcinoma (1)
- renal dysfunction (1)
- renal failure (1)
- renal tubular epithelial cells (1)
- research database (1)
- research funding (1)
- resectability (1)
- resin nano ceramics (1)
- resistance (1)
- resistance mutation (1)
- resolution (1)
- response (1)
- response inhibition (1)
- resting-state (1)
- reticulocyte hemoglobin equivalent (1)
- retrospective studies (1)
- reverberation (1)
- revision knee arthroplasty (1)
- reward (1)
- reward probabilities (1)
- rheumatoid arthritis (1)
- rifampicin (1)
- risk group (1)
- risk stratification (1)
- room simulation (1)
- safety attitudes questionnaire (1)
- salience network (1)
- saliva (1)
- salvage mastectomy (1)
- salvage radical prostatectomy (1)
- sampling (1)
- sarcoma (1)
- scar (1)
- schizophrenia (1)
- screening questionnaire (1)
- searchlight analysis (1)
- second line therapy (1)
- second-line immunotherapy (1)
- second-line treatment / 2L treatment (1)
- secondary data analysis (1)
- secondary progressive multiple sclerosis (1)
- secreted Ly-6/uPAR-related protein 1 (1)
- seed and soil (1)
- self-collected samples (1)
- semiquinone (1)
- sensory loss (1)
- sensory organ development (1)
- serine protease (NS3-4A) (1)
- serum (1)
- severely injured patient (1)
- sex (1)
- sexual arousal (1)
- sexual dysfunction (1)
- sexual rehabilitation (1)
- shared decision-making (1)
- shear stress (1)
- shikonin (SHI) (1)
- short bowel (1)
- short linear motif (1)
- short-term (1)
- shoulder instability (1)
- shoulder stabilization (1)
- simulation (1)
- simulation training (1)
- sleep deprivation (1)
- sleep disordered breathing (1)
- small bowel (1)
- small ubiquitin-related modifier (1)
- social anxiety (1)
- social communication (1)
- socio-economic influences (1)
- socioeconomic factors (1)
- soft tissue (1)
- soft tissue sarcoma (1)
- solid tumor (1)
- sonoSens (1)
- sorafenib (1)
- sound-induced flash illusion (1)
- spared nerve injury (1)
- speech perception (1)
- sphingolipids (1)
- sphingosine-1-phosphate (1)
- spike mutation (1)
- spike protein (1)
- spina bifida (1)
- spinal bone metastasis (1)
- spinal infection (1)
- spine injury (1)
- spinocerebellar ataxia (1)
- splicing (1)
- split-mouth (1)
- sprouting (1)
- sprouting angiogenesis (1)
- stage (1)
- stage migration (1)
- statin (1)
- statin treatment (1)
- statins (1)
- stoma (1)
- structure-function (1)
- strumpellin (1)
- stuttering (1)
- subarachnoid hemorrhage (1)
- subchondral bone (1)
- subgrouping (1)
- subpopulation (1)
- sulforaphane (1)
- sulfur-oxidizing symbiont (1)
- superparamagnetic iron oxide nanoparticles (1)
- support (1)
- suprachiasmatic nucleus (1)
- surgical complications (1)
- surrogate ELISA (1)
- symbiosis (1)
- symptoms (1)
- synoviocytes (1)
- synovitis (1)
- systematic review (1)
- tDCS (1)
- tVNS (1)
- tachycardia (1)
- target (1)
- targeted axillary dissection (1)
- targeted sequencing (1)
- taste buds (1)
- temporal encephaloceles (1)
- temporal lobe epilepsy (1)
- testosterone (1)
- tetracycline (1)
- tetrahydrobiopterin (1)
- tetrahydrocannabinol (1)
- therapy (1)
- therapy response (1)
- thermal ablation (1)
- thrombectomy (1)
- thromboembolism (1)
- thymic selection (1)
- tibial fracture (1)
- tip cell filopodia formation (1)
- tissue reconstruction (1)
- toddler’s fracture (1)
- tolerability (1)
- topical administration (1)
- topographical pattern (1)
- torticollis (1)
- total hip replacement (1)
- toxic milk mice (TX mice) (1)
- toxicity (1)
- traditional Chinese medicine (TCM) (1)
- trafficking (1)
- training (1)
- transduction (1)
- transfer entropy (1)
- transglutaminase (1)
- transient elastography (1)
- transjugular intrahepatic portosystemic shunt (1)
- translational investigation (1)
- translational study (1)
- transmission (1)
- transovarial transmission (1)
- transplant-free survival (1)
- transstadial transmission (1)
- trauma (1)
- traumatic brain injury (1)
- traumatic injury (1)
- treatment outcome (1)
- treatment resistance (1)
- treatment response (1)
- trials registry (1)
- triplex (1)
- trophoblast organoids (1)
- trophoblasts (1)
- trough levels (1)
- tumor immunity (1)
- tumor immunology (1)
- tumor stroma (1)
- tumor-associated macrophages (TAM) (1)
- tunnel technique (1)
- type 2 diabetes (1)
- tyrosine hydroxylase (1)
- tyrosine kinase inhibitor (TKI) (1)
- ubiquitin ligase (1)
- ultra-high risk for psychosis (1)
- unacceptable antigen mismatches (1)
- undifferentiated pleomorphic sarcoma (1)
- unilateral (1)
- unilateral hip osteoarthritis (1)
- upgrading (1)
- urethal stricture (1)
- urethroplasty (1)
- urinary incontinence (1)
- ursodeoxycholic acid (1)
- uveal melanoma (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- vaginal breech (1)
- vaginal hysterectomy (1)
- variants of concern (1)
- vascular biology (1)
- vasodilation (1)
- vector (1)
- venous thrombosis (1)
- ventral otoplasty (1)
- ventral striatum (1)
- ventricular tachycardia (1)
- vergence (1)
- vertigo (1)
- very high-risk (1)
- vestibular function (1)
- viral fitness (1)
- virus (1)
- viruses (1)
- volumetric measurement technology (1)
- von Willebrand disease (1)
- waiting time (1)
- walking (1)
- wearable sensors (1)
- weight reduction (1)
- white matter hyperintensity (1)
- whole-genome sequencing (1)
- work place evaluation (1)
- wound exudate (1)
- wound healing (1)
- wound infection (1)
- wound repair (1)
- yellow flags (1)
- younger (1)
- zinc protoporphyrin (1)
- Übergewicht (1)
- ß-amyloid (1)
- β-HCG (1)
Institute
- Medizin (662)
- Biochemie, Chemie und Pharmazie (8)
- Biowissenschaften (7)
- Psychologie und Sportwissenschaften (6)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (5)
- Georg-Speyer-Haus (4)
- Physik (3)
- Biodiversität und Klima Forschungszentrum (BiK-F) (2)
- Ernst Strüngmann Institut (2)
- Erziehungswissenschaften (2)
Background: Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base. Methods: We reviewed studies with more than 2000 participants or meta-analyses from five or more studies or 2000 or more participants. We excluded meta-analyses that did not assess publication bias, except for meta-analyses of prevalence. For network meta-analyses we required comparison adjusted funnel plots. We excluded treatment studies with waiting-list or treatment as usual controls. From this literature, we extracted evidence-based assertions about the disorder. Results: We generated 208 empirically supported statements about ADHD. The status of the included statements as empirically supported is approved by 80 authors from 27 countries and 6 continents. The contents of the manuscript are endorsed by 366 people who have read this document and agree with its contents. Conclusions: Many findings in ADHD are supported by meta-analysis. These allow for firm statements about the nature, course, outcome causes, and treatments for disorders that are useful for reducing misconceptions and stigma.
Background: Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to the clinical disease course versus later intervention. Methods: and analysis Here we present the rationale and design of a phase 3b, randomised, double-blind, multicentre study (GUIDE), comparing treatment effects of guselkumab in patients with short (≤2 years) or longer (>2 years) duration of plaque-type psoriasis, measured from first appearance of psoriatic plaques. Participants achieving skin clearance (Psoriasis Area and Severity Index (PASI)=0) by week 20 and maintaining complete clearance at week 28 visit (‘super-responders’ (SRe)) will be randomised to continue approved maintenance dosing every 8 weeks (q8w) versus an investigational maintenance dosing interval of 16 weeks (q16w) until week 68. Primary endpoint: proportion of participants in the q8w vs q16w arms with absolute PASI <3 at week 68. Participants with PASI <3 at week 68 will be withdrawn from guselkumab treatment for up to 48 weeks. Participants not achieving SRe criteria (non-SRe) will remain in the study with q8w guselkumab dosing through week 68. Additional to serum samples obtained from all patients, skin biopsies and whole-blood samples will be taken from SRe and non-SRe participants at various time points in optional substudies. Analyses include: genetics; immunophenotyping (fluorescence-activated cell sorting); gene and protein expression profiling; immunohistology. By merging clinical endpoints with mechanistic findings, this study aims to elucidate how IL-23 blockade with guselkumab can modify the disease course by altering molecular and cellular drivers that cause relapse after treatment withdrawal, particularly among SRe. Ethics and dissemination: Approval obtained from ethics committee Medical Council Hamburg, Germany (PVN5925). GUIDE is compliant with the Declaration of Helsinki. Trial registration number: Registered at ClinicalTrials.gov (NCT03818035). All primary endpoint results (prespecified analyses) will be submitted to peer-reviewed, international journals within 18 months after primary completion date.
Circulating P2X7 receptor signaling components as diagnostic biomarkers for temporal lobe epilepsy
(2021)
Circulating molecules have potential as biomarkers to support the diagnosis of epilepsy and to assist with differential diagnosis, for example, in conditions resembling epilepsy, such as in psychogenic non-epileptic seizures (PNES). The P2X7 receptor (P2X7R) is an important regulator of inflammation and mounting evidence supports its activation in the brain during epilepsy. Whether the P2X7R or P2X7R-dependent signaling molecules can be used as biomarkers of epilepsy has not been reported. P2X7R levels were analyzed by quantitative ELISA using plasma samples from controls and patients with temporal lobe epilepsy (TLE) or PNES. Moreover, blood cell P2X7R expression and P2X7R-dependent cytokine signature was measured following status epilepticus in P2X7R-EGFP reporter, wildtype, and P2X7R-knockout mice. P2X7R plasma levels were higher in TLE patients when compared with controls and patients with PNES. Plasma levels of the broad inflammatory marker protein C-Reactive protein (CRP) were similar between the three groups. Using P2X7R-EGFP reporter mice, we identified monocytes as the main blood cell type expressing P2X7R after experimentally evoked seizures. Finally, cytokine array analysis in P2X7R-deficient mice identified KC/GRO as a potential P2X7R-dependent plasma biomarker following status epilepticus and during epilepsy. Our data suggest that P2X7R signaling components may be a promising subclass of circulating biomarkers to support the diagnosis of epilepsy.
Objective: The NADPH oxidase Nox4 is an important source of H2O2. Nox4-derived H2O2 limits vascular inflammation and promotes smooth muscle differentiation. On this basis, the role of Nox4 for restenosis development was determined in the mouse carotid artery injury model. Methods and results: Genetic deletion of Nox4 by a tamoxifen-activated Cre-Lox-system did not impact on neointima formation in the carotid artery wire injury model. To understand this unexpected finding, time-resolved single-cell RNA-sequencing (scRNAseq) from injured carotid arteries of control mice and massive-analysis-of-cDNA-ends (MACE)-RNAseq from the neointima harvested by laser capture microdissection of control and Nox4 knockout mice was performed. This revealed that resting smooth muscle cells (SMCs) and fibroblasts exhibit high Nox4 expression, but that the proliferating de-differentiated SMCs, which give rise to the neointima, have low Nox4 expression. In line with this, the first weeks after injury, gene expression was unchanged between the carotid artery neointimas of control and Nox4 knockout mice. Conclusion: Upon vascular injury, Nox4 expression is transiently lost in the cells which comprise the neointima. NADPH oxidase 4 therefore does not interfere with restenosis development after wire-induced vascular injury.
Background: To identify variables predicting outcome in neuroblastoma patients assigned to the high-risk group solely by the presence of MYCN oncogene amplification (MNA). Methods: Clinical characteristics, genomic information, and outcome of 190 patients solely assigned to high-risk neuroblastoma by MNA were analyzed and compared to 205 patients with stage 4 neuroblastoma aged ≥18 months with MNA (control group). Results: Event-free survival (EFS) and overall survival (OS) at 10 years were 47% (95%-CI 39–54%) and 56% (95%-CI 49–63%), respectively, which was significantly better than EFS and OS of the control group (EFS 25%, 95%-CI 18–31%, p < 0.001; OS 32% 95%-CI 25–39%, p < 0.001). The presence of RAS-/p53-pathway gene alterations was associated with impaired 10-year EFS and OS (19% vs. 55%, and 19% vs. 67%, respectively; both p < 0.001). In time-dependent multivariable analyses, alterations of RAS-/p53-pathway genes and the extent of the best primary tumor resection were the only independent prognostic variables for OS (p < 0.001 and p = 0.011, respectively). Conclusions: Neuroblastoma patients attributed to high risk solely by MYCN amplification have generally a more favorable outcome. Mutations of genes of the RAS and/or p53 pathways and incomplete resection are the main risk factors predicting poor outcome.
Background: Bipolar disorder is associated with circadian disruption and a high risk of suicidal behavior. In a previous exploratory study of patients with bipolar I disorder, we found that a history of suicide attempts was associated with differences between winter and summer levels of solar insolation. The purpose of this study was to confirm this finding using international data from 42% more collection sites and 25% more countries. Methods: Data analyzed were from 71 prior and new collection sites in 40 countries at a wide range of latitudes. The analysis included 4876 patients with bipolar I disorder, 45% more data than previously analyzed. Of the patients, 1496 (30.7%) had a history of suicide attempt. Solar insolation data, the amount of the sun’s electromagnetic energy striking the surface of the earth, was obtained for each onset location (479 locations in 64 countries). Results: This analysis confirmed the results of the exploratory study with the same best model and slightly better statistical significance. There was a significant inverse association between a history of suicide attempts and the ratio of mean winter insolation to mean summer insolation (mean winter insolation/mean summer insolation). This ratio is largest near the equator which has little change in solar insolation over the year, and smallest near the poles where the winter insolation is very small compared to the summer insolation. Other variables in the model associated with an increased risk of suicide attempts were a history of alcohol or substance abuse, female gender, and younger birth cohort. The winter/summer insolation ratio was also replaced with the ratio of minimum mean monthly insolation to the maximum mean monthly insolation to accommodate insolation patterns in the tropics, and nearly identical results were found. All estimated coefficients were significant at p < 0.01. Conclusion: A large change in solar insolation, both between winter and summer and between the minimum and maximum monthly values, may increase the risk of suicide attempts in bipolar I disorder. With frequent circadian rhythm dysfunction and suicidal behavior in bipolar disorder, greater understanding of the optimal roles of daylight and electric lighting in circadian entrainment is needed.
Introduction: The newest intravenous (IV) iron products show an improved safety profile over predecessors, allowing for the rapid administration of relatively high doses. Ferric derisomaltose (FDI; also known as iron isomaltoside), ferric carboxymaltose (FCM), and ferumoxytol (FER), are successful treatments for iron deficiency (Europe; FDI and FCM) and iron deficiency anemia (US; FDI, FCM, and FER). Areas covered: This review focusses on the chemistry and structure of FDI, FCM, and FER, and on three key aspects of IV iron safety: (1) hypersensitivity; (2) hypophosphatemia and sequelae; (3) cardiovascular safety. Expert opinion: Although the safety of modern IV iron has improved, immediate infusion reactions and the development of hypophosphatemia must be appreciated and recognized by those who prescribe and administer IV iron. Immediate infusion reactions can occur with any IV iron and are usually mild; severe reactions – particularly anaphylaxis – are extremely rare. The recognition and appropriate management of infusion reactions is an important consideration to the successful administration of IV iron. Severe, persistent, hypophosphatemia is a specific side effect of FCM. No cardiovascular safety signal has been identified for IV iron. Ongoing trials in heart failure will provide additional long-term efficacy and safety data.
Background: The aim of this study was to evaluate the longer-term results of bicuspid aortic valve (BAV) repair with or without aortic root replacement. Methods: From 1999 to 2017, 142 patients with or without aortic root dilatation who underwent repair of a regurgitant BAV were included in the study. Ninety-four patients underwent isolated BAV repair (Group 1; median age 43 years) and 48 patients underwent valve-sparing aortic root replacement plus BAV repair (aortic valve reimplantation—Group 2; median age 48 years). Median clinical follow-up time was 5.9 years (range 0.5–15) in Group 1 and 3 years (range 0.5–16) in Group 2, respectively. Results: In-hospital mortality was 1% in Group 1, and 2% in Group 2 (p = .6). The 5- and 10-year survival was 93 ± 2.9% and 81 ± 5.8% in Group 1 and 96 ± 3.1% and 96 ± 3.1% in Group 2, respectively (p = .31). Eleven patients of Group 1 (1.7%/patient-year) and five patients of Group 2 (2.2%/patient-year) underwent reoperation of the aortic valve (p = .5). The 5- and 10-year freedom from reoperation were 93.0 ± 2.1% and 77.1 ± 7.1% in Group 1 and 93.0 ± 5.0% and 76.7 ± 9.6% in Group 2 (p = .83), respectively. At the latest follow-up, only two patients of Group 1 and 1 patient of Group 2 had AV regurgitation = 2° (p = .7). The cumulative linearized incidence of all valve-related complications (bleeding, stroke, endocarditis, and reoperation) was 2.9%/patient-year in Group 1% and 4%/patient-year in Group 2, respectively (p = .6). Conclusions: Isolated BAV repair and combined aortic valve reimplantation plus BAV repair provide good clinical longer-term outcomes with relatively low reoperation rate and durable valve function.
Objective: Evaluation of survival of teeth with class III furcation involvement (FI) ≥5 years after active periodontal treatment (APT) and identification of prognostic factors. Methods: All charts of patients who completed APT at the Department of Periodontology of Goethe-University Frankfurt, Germany, beginning October 2004 were screened for teeth with class III FI. APT had to be accomplished for ≥5 years. Charts were analysed for data of class III FI teeth at baseline (T0), at accomplishment of APT (T1), and at the last supportive periodontal care (T2). Baseline radiographic bone loss (RBL) and treatment were assessed. Results: One-hundred and sixty patients (age: 54.4 ± 9.8 years; 82 females; 39 active smokers; 9 diabetics, 85 stage III, 75 stage IV, 59 grade B, 101 grade C) presented 265 teeth with class III FI. Ninety-eight teeth (37%) were lost during 110, 78/137 (median, lower/upper quartile) months. Logistic mixed-model regression and mixed Cox proportional hazard model associated adjunctive systemic antibiotics with fewer tooth loss (26% vs. 42%; p = .019/.004) and RBL (p = .014/.024) and mean probing pocket depth (PPD) at T1 (p < .001) with more tooth loss. Conclusions: Subgingival instrumentation with adjunctive systemic antibiotics favours retention of class III furcation-involved teeth. Baseline RBL and PPD at T1 deteriorate long-term prognosis.
Objective: This study was undertaken to evaluate the long-term efficacy, retention, and tolerability of add-on brivaracetam (BRV) in clinical practice. Methods: A multicenter, retrospective cohort study recruited all patients who initiated BRV between February and November 2016, with observation until February 2021. Results: Long-term data for 262 patients (mean age = 40 years, range = 5–81 years, 129 men) were analyzed, including 227 (87%) diagnosed with focal epilepsy, 19 (7%) with genetic generalized epilepsy, and 16 (6%) with other or unclassified epilepsy syndromes. Only 26 (10%) patients had never received levetiracetam (LEV), whereas 133 (50.8%) were switched from LEV. The length of BRV exposure ranged from 1 day to 5 years, with a median retention time of 1.6 years, resulting in a total BRV exposure time of 6829 months (569 years). The retention rate was 61.1% at 12 months, with a reported efficacy of 33.1% (79/239; 50% responder rate, 23 patients lost-to-follow-up), including 10.9% reported as seizure-free. The retention rate for the entire study period was 50.8%, and at last follow-up, 133 patients were receiving BRV at a mean dose of 222 ± 104 mg (median = 200, range = 25–400), including 52 (39.1%) who exceeded the recommended upper dose of 200 mg. Fewer concomitant antiseizure medications and switching from LEV to BRV correlated with better short-term responses, but no investigated parameters correlated with positive long-term outcomes. BRV was discontinued in 63 (24%) patients due to insufficient efficacy, in 29 (11%) for psychobehavioral adverse events, in 25 (10%) for other adverse events, and in 24 (9%) for other reasons. Significance: BRV showed a clinically useful 50% responder rate of 33% at 12 months and overall retention of >50%, despite 90% of included patients having previous LEV exposure. BRV was well tolerated; however, psychobehavioral adverse events occurred in one out of 10 patients. Although we identified short-term response and retention predictors, we could not identify significant predictors for long-term outcomes. Key Points Long-term postmarketing data for brivaracetam in 262 patients showed an overall retention rate of 50.8%; At 12 months, the 50% responder rate for brivaracetam was 33.1%, with 10.9% reporting seizure freedom; Previous treatment with levetiracetam (90%) did not impact brivaracetam retention or efficacy; Levetiracetam treatment failure should not preclude brivaracetam introduction; No long-term efficacy predictors could be identified.
Musculoskeletal disorders of the trunk and neck are common among cleaners. Vacuum cleaning is a demanding activity. The aim of this study was to present the movement profile of the trunk and neck during habitual vacuuming. The data were collected from 31 subjects (21f./10 m) using a 3D motion analysis system (Xsens). 10 cycles were analysed in vacuuming PVC and carpet floors with 8 vacuum cleaners. The joint angles and velocities were represented statistically descriptive. When vacuuming, the trunk is held in a forwardly inclined position by a flexion in the hip and rotated from this position. In the joint angles and velocities of the spine, the rotation proved to be dominant. A relatively large amount of movement took place in the cervical spine and also in the lumbar spine. The shown movement profile is rather a comfort area of vacuuming which may serve as a reference for ergonomics in vacuuming.
Purpose: To compare Cancer-specific mortality (CSM) in patients with Squamous cell carcinoma (SCC) vs. non-SCC penile cancer, since survival outcomes may differ between histological subtypes. Methods: Within the Surveillance, Epidemiology and End Results database (2004–2016), penile cancer patients of all stages were identified. Temporal trend analyses, cumulative incidence and Kaplan–Meier plots, multivariable Cox regression and Fine and Gray competing-risks regression analyses tested for CSM differences between non-SCC vs. SCC penile cancer patients. Results: Of 4,120 eligible penile cancer patients, 123 (3%) harbored non-SCC vs. 4,027 (97%) SCC. Of all non-SCC patients, 51 (41%) harbored melanomas, 42 (34%) basal cell carcinomas, 10 (8%) adenocarcinomas, eight (6.5%) skin appendage malignancies, six (5%) epithelial cell neoplasms, two (1.5%) neuroendocrine tumors, two (1.5%) lymphomas, two (1.5%) sarcomas. Stage at presentation differed between non-SCC vs. SCC. In temporal trend analyses, non-SCC diagnoses neither decreased nor increased over time (p > 0.05). After stratification according to localized, locally advanced, and metastatic stage, no CSM differences were observed between non-SCC vs. SCC, with 5-year survival rates of 11 vs 11% (p = 0.9) for localized, 33 vs. 37% (p = 0.4) for locally advanced, and 1-year survival rates of 37 vs. 53% (p = 0.9) for metastatic penile cancer, respectively. After propensity score matching for patient and tumor characteristics and additional multivariable adjustment, no CSM differences between non-SCC vs. SCC were observed. Conclusion: Non-SCC penile cancer is rare. Although exceptions exist, on average, non-SCC penile cancer has comparable CSM as SCC penile cancer patients, after stratification for localized, locally invasive, and metastatic disease.
Purpose: In patients with pyogenic spondylodiscitis, surgery is considered the treatment of choice to conduct proper debridement, stabilise the spine and avoid extended bed rest, which in turn is a risk factor for complications such as deep vein thrombosis and pulmonary embolism. Methods: We conducted a retrospective clinical study with analysis of a group of 99 patients who had undergone treatment for pyogenic discitis at our institution between June 2012 and August 2017. Included parameters were age, sex, disease pattern, the presence of deep vein thrombosis, resuscitation, in-hospital mortality, present anticoagulation, preexisting comorbidities, tobacco abuse, body mass index, microbiological germ detection and laboratory results. Results: Among the analysed cohort, 12% of the treated patients for pyogenic spondylodiscitis suffered from a radiologically confirmed pulmonary embolism. Coronary heart disease (p < 0.01), female sex (p < 0.01), anticoagulation at admission (p < 0.01) and non-O blood type (p < 0.001) were associated with development of pulmonary embolism. Pulmonary embolism was significantly associated with resuscitation (p < 0.005) and deep vein thrombosis (p < 0.001). Neurosurgery was not associated with increased risk for pulmonary embolism compared to conservative-treated patients (p > 0.05). Conclusion: Surgery for pyogenic spondylodiscitis was not associated with an elevated risk of pulmonary embolism in our analysis. However, we describe several risk factors for pulmonary embolism in this vulnerable cohort. Prospective studies are necessary to improve prevention and postoperative management in patients with pyogenic spondylodiscitis.
HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders
(2021)
Bipolar affective disorder (BD) is a severe psychiatric illness, for which lithium (Li) is the gold standard for acute and maintenance therapies. The therapeutic response to Li in BD is heterogeneous and reliable biomarkers allowing patients stratification are still needed. A GWAS performed by the International Consortium on Lithium Genetics (ConLiGen) has recently identified genetic markers associated with treatment responses to Li in the human leukocyte antigens (HLA) region. To better understand the molecular mechanisms underlying this association, we have genetically imputed the classical alleles of the HLA region in the European patients of the ConLiGen cohort. We found our best signal for amino-acid variants belonging to the HLA-DRB1*11:01 classical allele, associated with a better response to Li (p < 1 × 10−3; FDR < 0.09 in the recessive model). Alanine or Leucine at position 74 of the HLA-DRB1 heavy chain was associated with a good response while Arginine or Glutamic acid with a poor response. As these variants have been implicated in common inflammatory/autoimmune processes, our findings strongly suggest that HLA-mediated low inflammatory background may contribute to the efficient response to Li in BD patients, while an inflammatory status overriding Li anti-inflammatory properties would favor a weak response.
TRIANNI mice carry an entire set of human immunoglobulin V region gene segments and are a powerful tool to rapidly isolate human monoclonal antibodies. After immunizing these mice with DNA encoding the spike protein of SARS-CoV-2 and boosting with spike protein, we identified 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein. Nine antibodies neutralize SARS-CoV-2 infection at IC50 values in the subnanomolar range. ELISA-binding studies and DNA sequence analyses revealed one cluster of three clonally related neutralizing antibodies that target the receptor-binding domain and compete with the cellular receptor hACE2. A second cluster of six clonally related neutralizing antibodies bind to the N-terminal domain of the spike protein without competing with the binding of hACE2 or cluster 1 antibodies. SARS-CoV-2 mutants selected for resistance to an antibody from one cluster are still neutralized by an antibody from the other cluster. Antibodies from both clusters markedly reduced viral spread in mice transgenic for human ACE2 and protected the animals from SARS-CoV-2-induced weight loss. The two clusters of potent noncompeting SARS-CoV-2 neutralizing antibodies provide potential candidates for therapy and prophylaxis of COVID-19. The study further supports transgenic animals with a human immunoglobulin gene repertoire as a powerful platform in pandemic preparedness initiatives.
Background: Cases of immune complex vasculitis have been reported following COVID-19 infections; so far none in association with novel mRNA-based COVID-19 vaccination. This case report describes a cutaneous immune complex vasculitis after vaccination with BNT162b2. Case presentation: A 76-year old male with liver cirrhosis developed an immune complex vasculitis 12 days after the second injection of BNT162b2. On physical examination, the patient presented with pruritic purpuric macules on hands and feet, flexor and extensor parts of both legs and thighs and lower abdomen, and bloody diarrhoea. Laboratory testing showed elevated inflammatory markers. After short treatment with oral steroids all clinical manifestations and laboratory findings resolved. Conclusions: An increasing number of clinical manifestations have been attributed to COVID-19 infection and vaccination. This is the first written report of immune complex vasculitis after vaccination with BNT162b2. We present our case report and a discussion in the light of type three hypersensitivity reaction.
Rationale: Both attention deficit-/hyperactivity disorder (ADHD) and alcohol use disorder (AUD) are accompanied by deficits in response inhibition. Furthermore, the prevalence of comorbidity of ADHD and AUD is high. However, there is a lack of research on whether the same neuronal subprocesses of inhibition (i.e., interference inhibition, action withholding and action cancellation) exhibit deficits in both psychiatric disorders. Methods: We examined these three neural subprocesses of response inhibition in patient groups and healthy controls: non-medicated individuals with ADHD (ADHD; N = 16), recently detoxified and abstinent individuals with alcohol use disorder (AUD; N = 15), and healthy controls (HC; N = 15). A hybrid response inhibition task covering interference inhibition, action withholding, and action cancellation was applied using a 3T functional magnetic resonance imaging (fMRI). Results: Individuals with ADHD showed an overall stronger hypoactivation in attention related brain areas compared to AUD or HC during action withholding. Further, this hypoactivation was more accentuated during action cancellation. Individuals with AUD recruited a broader network, including the striatum, compared to HC during action withholding. During action cancellation, however, they showed hypoactivation in motor regions. Additionally, specific neural activation profiles regarding group and subprocess became apparent. Conclusions: Even though deficits in response inhibition are related to both ADHD and AUD, neural activation and recruited networks during response inhibition differ regarding both neuronal subprocesses and examined groups. While a replication of this study is needed in a larger sample, the results suggest that tasks have to be carefully selected when examining neural activation patterns of response inhibition either in research on various psychiatric disorders or transdiagnostic questions.
Introduction: In an emergency department, the majority of pediatric trauma patients present because of minor injuries. The aim of this study was to evaluate temporal changes in age-related injury pattern, trauma mechanism, and surgeries in pediatric patients. Methods: This retrospective study included patients < 18 years of age following trauma from 01/2009 to 12/2018 at a level I trauma center. They were divided into two groups: group A (A: 01/2009 to 12/2013) and group B (B: 01/2014 to 12/2018). Injury mechanism, injury pattern, and surgeries were analyzed. As major injuries fractures, dislocations, and organ injuries and as minor injuries contusions and superficial wounds were defined. Results: 23,582 patients were included (58% male, median age 8.2 years). There was a slight increase in patients comparing A (n = 11,557) and B (n = 12,025) with no difference concerning demographic characteristics. Significant more patients (A: 1.9%; B: 2.4%) were admitted to resuscitation room, though the number of multiple injured patients was not significantly different. In A (25.5%), major injuries occurred significantly less frequently than in B (27.0%), minor injuries occurred equally. Extremity fractures were significantly more frequent in B (21.5%) than in A (20.2%), peaking at 8–12 years. Most trauma mechanisms of both groups were constant, with a rising of sport injuries at 8–12 years. Conclusion: Although number of patients increases only slightly over a decade, there was a clear increase in major injuries, particularly extremity fractures, peaking at 8–12 years. At this age also sport accidents significantly increased. At least, admittance to resuscitation room rose but without an increase of multiple injured patients.
Introduction: Improvements in both musculoskeletal and non-musculoskeletal manifestations are important treatment goals in psoriatic arthritis (PsA). Objective: These post hoc analyses determined whether additional benefits related to various PsA domains are observed in patients simultaneously achieving 50% improvement in American College of Rheumatology criteria (ACR50) and 100% improvement in Psoriasis Area Severity Index (PASI100), the primary endpoint of the SPIRIT-H2H study. Methods: Patients with active PsA and psoriasis in SPIRIT-H2H (N = 566) were categorised into two sets of four response groups irrespective of treatment allocation (approved dosages of ixekizumab or adalimumab): patients who simultaneously achieved ACR50 and PASI100 response, achieved ACR50 response only, achieved PASI100 response only, or did not achieve ACR50 or PASI100 response after 24 and 52 weeks of treatment. Patients achieving simultaneous ACR50 and PASI100 response were compared with the other patient response groups at the corresponding time point for efficacy and health-related quality of life (HRQoL) outcomes. Results: Patients simultaneously achieving ACR50 and PASI100 responses at week 24 or 52 showed higher rates of ACR70 response, minimal disease activity, Disease Activity in Psoriatic Arthritis ≤ 4, resolution of enthesitis and dactylitis, and HRQoL improvement at weeks 24 and 52, respectively, than the other corresponding response groups at both time points. Conclusion: High levels of disease control, such as those obtained with simultaneous achievement of ACR50 and PASI100 response, were linked to better outcomes across a wide range of endpoints that are important for patients with PsA. Patients meeting this combined endpoint showed more comprehensive and thus greater control of disease activity.
Background: Due to the coronavirus disease 2019 (COVID-19) pandemic, interventions in the upper airways are considered high-risk procedures for otolaryngologists and their colleagues. The purpose of this study was to evaluate limitations in hearing and communication when using a powered air-purifying respirator (PAPR) system to protect against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) transmission and to assess the benefit of a headset. Methods: Acoustic properties of the PAPR system were measured using a head and torso simulator. Audiological tests (tone audiometry, Freiburg speech test, Oldenburg sentence test (OLSA)) were performed in normal-hearing subjects (n = 10) to assess hearing with PAPR. The audiological test setup also included simulation of conditions in which the target speaker used either a PAPR, a filtering face piece (FFP) 3 respirator, or a surgical face mask. Results: Audiological measurements revealed that sound insulation by the PAPR headtop and noise, generated by the blower-assisted respiratory protection system, resulted in significantly deteriorated hearing thresholds (4.0 ± 7.2 dB hearing level (HL) vs. 49.2 ± 11.0
Objectives: To evaluate the predictive value of volumetric bone mineral density (BMD) assessment of the lumbar spine derived from phantomless dual-energy CT (DECT)-based volumetric material decomposition as an indicator for the 2-year occurrence risk of osteoporosis-associated fractures. Methods: L1 of 92 patients (46 men, 46 women; mean age, 64 years, range, 19–103 years) who had undergone third-generation dual-source DECT between 01/2016 and 12/2018 was retrospectively analyzed. For phantomless BMD assessment, dedicated DECT postprocessing software using material decomposition was applied. Digital files of all patients were sighted for 2 years following DECT to obtain the incidence of osteoporotic fractures. Receiver operating characteristic (ROC) analysis was used to calculate cut-off values and logistic regression models were used to determine associations of BMD, sex, and age with the occurrence of osteoporotic fractures. Results: A DECT-derived BMD cut-off of 93.70 mg/cm3 yielded 85.45% sensitivity and 89.19% specificity for the prediction to sustain one or more osteoporosis-associated fractures within 2 years after BMD measurement. DECT-derived BMD was significantly associated with the occurrence of new fractures (odds ratio of 0.8710, 95% CI, 0.091–0.9375, p < .001), indicating a protective effect of increased DECT-derived BMD values. Overall AUC was 0.9373 (CI, 0.867–0.977, p < .001) for the differentiation of patients who sustained osteoporosis-associated fractures within 2 years of BMD assessment. Conclusions: Retrospective DECT-based volumetric BMD assessment can accurately predict the 2-year risk to sustain an osteoporosis-associated fracture in at-risk patients without requiring a calibration phantom. Lower DECT-based BMD values are strongly associated with an increased risk to sustain fragility fractures.
Key Points: Dual-energy CT–derived assessment of bone mineral density can identify patients at risk to sustain osteoporosis-associated fractures with a sensitivity of 85.45% and a specificity of 89.19%. The DECT-derived BMD threshold for identification of at-risk patients lies above the American College of Radiology (ACR) QCT guidelines for the identification of osteoporosis (93.70 mg/cm 3 vs 80 mg/cm 3 ).
To explore and describe attitudes and opinions towards suicidality in healthcare professionals (HCPs) working with oncological patients. Methods: A 48-item online questionnaire was developed and distributed to HCPs working with cancer patients. Three hundred fifty-four answered questionnaires were analyzed. Results: The majority of HCPs reported that they were able to understand why a cancer patient would commit suicide (87.8%) or would seek help from an assisted suicide organization (ASO; 83.9%). The understandable reasons were pain and physical impairments (51.4%), social isolation (19.8%), loss of control and autonomy (18.1%), terminal disease (17.2%), loss of meaning (15.3%), desperation (14.7%), and psychic distress (9.3%). Personal experiences with suicidality lead only 44.8% of HCPs to believe that thereby they would be better able to understand a patients’ wish for suicide. Religion was negatively associated with understanding of suicide and why a cancer patient would seek help from an ASO. Knowledge of suicidality was positively associated with why a cancer patient would seek help from an ASO. Conclusions: There is still little knowledge in oncology about the relation of HCPs’ attitudes toward suicidality in their patients and how those attitudes influence their behavior, especially care and treatment of patients. More research on this topic is needed. It stands to reason that more education about suicidality in cancer patients seems likely to improve understanding and attitudes and thereby influence care for cancer patients.
Background: Dual-source dual-energy computed tomography (DECT) offers the potential for opportunistic osteoporosis screening by enabling phantomless bone mineral density (BMD) quantification. This study sought to assess the accuracy and precision of volumetric BMD measurement using dual-source DECT in comparison to quantitative CT (QCT). Methods: A validated spine phantom consisting of three lumbar vertebra equivalents with 50 (L1), 100 (L2), and 200 mg/cm3 (L3) calcium hydroxyapatite (HA) concentrations was scanned employing third-generation dual-source DECT and QCT. While BMD assessment based on QCT required an additional standardised bone density calibration phantom, the DECT technique operated by using a dedicated postprocessing software based on material decomposition without requiring calibration phantoms. Accuracy and precision of both modalities were compared by calculating measurement errors. In addition, correlation and agreement analyses were performed using Pearson correlation, linear regression, and Bland-Altman plots. Results: DECT-derived BMD values differed significantly from those obtained by QCT (p < 0.001) and were found to be closer to true HA concentrations. Relative measurement errors were significantly smaller for DECT in comparison to QCT (L1, 0.94% versus 9.68%; L2, 0.28% versus 5.74%; L3, 0.24% versus 3.67%, respectively). DECT demonstrated better BMD measurement repeatability compared to QCT (coefficient of variance < 4.29% for DECT, < 6.74% for QCT). Both methods correlated well to each other (r = 0.9993; 95% confidence interval 0.9984–0.9997; p < 0.001) and revealed substantial agreement in Bland-Altman plots. Conclusions: Phantomless dual-source DECT-based BMD assessment of lumbar vertebra equivalents using material decomposition showed higher diagnostic accuracy compared to QCT.
We investigated the effects of sexual arousal induced by olfactory stimuli on the expression of neuromodulators, neurotransmitters and sexual steroid receptors in the suprachiasmatic nucleus (SCN, the circadian pacemaker of mammals) and other cerebral entities of Syrian hamsters (Mesocricetus auratus) compared to manual sleep deprivation and immobilization stress. The hamsters kept under a 12:12 hours (h) light:dark cycle were deprived of sleep by sexual stimulation, gentle manual handling or immobilization stress for 1 h at the beginning of the light phase and subsequently sacrificed at zeitgeber time 01:00, respectively; for comparison, hamsters were manually sleep deprived for 6 or 20 h or sacrificed after completing a full sleep phase. As demonstrated by immunohistochemistry, apart from various alterations after manual sleep deprivation, sexual stimulation caused down-regulation of arginine-vasopressin (AVP), vasointestinal peptide (VIP), serotonin (5-HT), substance P (SP), and met-enkephalin (ME) in the SCN. Somatostatin (SOM) was diminished in the medial periventricular nucleus (MPVN). In contrast, an increase in AVP was observed in the PVN, that of oxytocin (OXY) in the supraoptic nucleus (SON), of tyrosine-hydroxylase (TH) in the infundibular nucleus (IN), and dopamine beta-hydroxylase (DBH) in the A7 neuron population of the brain stem (A7), respectively. Testosterone in plasma was increased. The results indicate that sexual arousal extensively influences the neuropeptide systems of the SCN, suggesting an involvement of the SCN in reproductive behavior.
Rodent models of Parkinson’s disease are based on transgenic expression of mutant synuclein, deletion of PD genes, injections of MPTP or rotenone, or seeding of synuclein fibrils. The models show histopathologic features of PD such as Lewi bodies but mostly only subtle in vivo manifestations or systemic toxicity. The models only partly mimic a predominant loss of dopaminergic neurons in the substantia nigra. We therefore generated mice that express the transgenic diphtheria toxin receptor (DTR) specifically in DA neurons by crossing DAT-Cre mice with Rosa26 loxP-STOP-loxP DTR mice. After defining a well-tolerated DTx dose, DAT-DTR and DTR-flfl controls were subjected to non-toxic DTx treatment (5 × 100 pg/g) and subsequent histology and behavioral tests. DAT protein levels were reduced in the midbrain, and tyrosine hydroxylase-positive neurons were reduced in the substantia nigra, whereas the pan-neuronal marker NeuN was not affected. Despite the promising histologic results, there was no difference in motor function tests or open field behavior. These are tests in which double mutant Pink1−/−SNCAA53T Parkinson mice show behavioral abnormalities. Higher doses of DTx were toxic in both groups. The data suggest that DTx treatment in mice with Cre/loxP-driven DAT-DTR expression leads to partial ablation of DA-neurons but without PD-reminiscent behavioral correlates.
Peptide receptor radionuclide therapy (PRRT) of metastatic neuroendocrine tumors (NET) can be successfully repeated but may eventually be dose-limited. Since 177Lu-DOTATATE dose limitation may come from hematological rather than renal function, hematological peripheral blood stem cell backup might be desirable. Here, we report our initial experience of peripheral blood stem-cell collection (PBSC) in patients with treatment-related cytopenia and therefore high risk of bone-marrow failure. Five patients with diffuse bone-marrow infiltration of NET and relevant myelosuppression (≥grade 2) received PBSC before one PRRT cycle with 177Lu-DOTATATE (7.6 ± 0.8 GBq/cycle). Standard stem-cell mobilization with Granulocyte-colony stimulating factor (G-CSF) was applied, and successful PBSC was defined as a collection of >2 × 106/kg CD34+ cells. In case of initial failure, Plerixafor was administered in addition to G-CSF prior to apheresis. PBSC was successfully performed in all patients with no adverse events. Median cumulative activity was 44.8 GBq (range, 21.3–62.4). Three patients had been previously treated with PRRT, two of which needed the addition of Plerixafor for stem-cell mobilization. Only one of five patients required autologous peripheral blood stem-cell transplantation during the median follow up time of 28 months. PBSC collection seems to be feasible in NET with bone-marrow involvement and might be worth considering as a backup strategy prior to PRRT, in order to overcome dose-limiting bone-marrow toxicity.
Gaining detailed knowledge about sex-related immunoregulation remains a crucial prerequisite for the development of adequate disease models and therapeutic strategies enabling personalized medicine. Here, the key parameter of the production of cytokines mediating disease resolution was investigated. Among these cytokines, STAT3-activating interleukin (IL)-22 is principally associated with recovery from tissue injury. By investigating paradigmatic acetaminophen-induced liver injury, we demonstrated that IL-22 expression is enhanced in female mice. Increased female IL-22 was confirmed at a cellular level using murine splenocytes stimulated by lipopolysaccharide or αCD3/CD28 to model innate or adaptive immunoactivation. Interestingly, testosterone or dihydrotestosterone reduced IL-22 production by female but not by male splenocytes. Mechanistic studies on PMA/PHA-stimulated T-cell-lymphoma EL-4 cells verified the capability of testosterone/dihydrotestosterone to reduce IL-22 production. Moreover, we demonstrated by chromatin immunoprecipitation that testosterone impairs binding of the aryl hydrocarbon receptor to xenobiotic responsive elements within the murine IL-22 promoter. Overall, female mice undergoing acute liver injury and cultured female splenocytes upon inflammatory activation display increased IL-22. This observation is likely related to the immunosuppressive effects of androgens in males. The data presented concur with more pronounced immunological alertness demonstrable in females, which may relate to the sex-specific course of some immunological disorders.
The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Most SARS-CoV-2 infections are mild or even asymptomatic. However, a small fraction of infected individuals develops severe, life-threatening disease, which is caused by an uncontrolled immune response resulting in hyperinflammation. However, the factors predisposing individuals to severe disease remain poorly understood. Here, we show that levels of CD47, which is known to mediate immune escape in cancer and virus-infected cells, are elevated in SARS-CoV-2-infected Caco-2 cells, Calu-3 cells, and air−liquid interface cultures of primary human bronchial epithelial cells. Moreover, SARS-CoV-2 infection increases SIRPalpha levels, the binding partner of CD47, on primary human monocytes. Systematic literature searches further indicated that known risk factors such as older age and diabetes are associated with increased CD47 levels. High CD47 levels contribute to vascular disease, vasoconstriction, and hypertension, conditions that may predispose SARS-CoV-2-infected individuals to COVID-19-related complications such as pulmonary hypertension, lung fibrosis, myocardial injury, stroke, and acute kidney injury. Hence, age-related and virus-induced CD47 expression is a candidate mechanism potentially contributing to severe COVID-19, as well as a therapeutic target, which may be addressed by antibodies and small molecules. Further research will be needed to investigate the potential involvement of CD47 and SIRPalpha in COVID-19 pathology. Our data should encourage other research groups to consider the potential relevance of the CD47/ SIRPalpha axis in their COVID-19 research.
Background: To test the effect of urological primary cancers (bladder, kidney, testis, upper tract, penile, urethral) on overall mortality (OM) after secondary prostate cancer (PCa). Methods: Within the Surveillance, Epidemiology and End Results (SEER) database, patients with urological primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion with primary PCa controls. OM was compared between secondary and primary PCa patients and stratified according to primary urological cancer type, as well as to time interval between primary urological cancer versus secondary PCa diagnoses. Results: We identified 5,987 patients with primary urological and secondary PCa (bladder, n = 3,287; kidney, n = 2,127; testis, n = 391; upper tract, n = 125; penile, n = 47; urethral, n = 10) versus 531,732 primary PCa patients. Except for small proportions of Gleason grade group and age at diagnosis, PCa characteristics between secondary and primary PCa were comparable. Conversely, proportions of secondary PCa patients which received radical prostatectomy were smaller (29.0 vs. 33.5%), while no local treatment rates were higher (34.2 vs. 26.3%). After 1:4 matching, secondary PCa patients exhibited worse OM than primary PCa patients, except for primary testis cancer. Here, no OM differences were recorded. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis. Conclusions: After detailed matching for PCa characteristics, secondary PCa patients exhibit worse survival, except for testis cancer patients. The survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary urological cancer diagnosis.
Objective: The term ‘precision medicine’ describes a rational treatment strategy tailored to one person that reverses or modifies the disease pathophysiology. In epilepsy, single case and small cohort reports document nascent precision medicine strategies in specific genetic epilepsies. The aim of this multicentre observational study was to investigate the deeper complexity of precision medicine in epilepsy. Methods: A systematic survey of patients with epilepsy with a molecular genetic diagnosis was conducted in six tertiary epilepsy centres including children and adults. A standardised questionnaire was used for data collection, including genetic findings and impact on clinical and therapeutic management. Results: We included 293 patients with genetic epilepsies, 137 children and 156 adults, 162 females and 131 males. Treatment changes were undertaken because of the genetic findings in 94 patients (32%), including rational precision medicine treatment and/or a treatment change prompted by the genetic diagnosis, but not directly related to known pathophysiological mechanisms. There was a rational precision medicine treatment for 56 patients (19%), and this was tried in 33/56 (59%) and was successful (ie, >50% seizure reduction) in 10/33 (30%) patients. In 73/293 (25%) patients there was a treatment change prompted by the genetic diagnosis, but not directly related to known pathophysiological mechanisms, and this was successful in 24/73 (33%). Significance: Our survey of clinical practice in specialised epilepsy centres shows high variability of clinical outcomes following the identification of a genetic cause for an epilepsy. Meaningful change in the treatment paradigm after genetic testing is not yet possible for many people with epilepsy. This systematic survey provides an overview of the current application of precision medicine in the epilepsies, and suggests the adoption of a more considered approach.
Abstract: Neurophysiological measures of preparation and attention are often atypical in ADHD. Still, replicated findings that these measures predict which patients improve after Neurofeedback (NF), reveal neurophysiological specificity, and reflect ADHD-severity are limited. Methods: We analyzed children’s preparatory (CNV) and attentional (Cue-P3) brain activity and behavioral performance during a cued Continuous Performance Task (CPT) before and after slow cortical potential (SCP)-NF or semi-active control treatment (electromyogram biofeedback). Mixed-effects models were performed with 103 participants at baseline and 77 were assessed for pre-post comparisons focusing on clinical outcome prediction, specific neurophysiological effects of NF, and associations with ADHD-severity. Results: Attentional and preparatory brain activity and performance were non-specifically reduced after treatment. Preparatory activity in the SCP-NF group increased with clinical improvement. Several performance and brain activity measures predicted non-specific treatment outcome. Conclusion: Specific neurophysiological effects after SCP-NF were limited to increased neural preparation associated with improvement on ADHD-subscales, but several performance and neurophysiological measures of attention predicted treatment outcome and reflected symptom severity in ADHD. The results may help to optimize treatment.
Background: Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment-naïve patients than in patients with refractory MSI-H/dMMR metastatic colorectal cancer and even more active in patients with locally advanced tumors. Material and Methods: A 33-year-old male patient with Lynch syndrome was diagnosed with a locally advanced rectal cancer and refused standard neoadjuvant chemoradiation because of the potential harm of sexual dysfunction. MMR and microsatellite instability status were analyzed by immunohistochemistry and fragment length polymerase chain reaction followed by capillary electrophoresis. Results: After MSI-H/dMMR was confirmed, the patient was treated with ICIs (1 mg/kg ipilimumab at day 1 and 3 mg/kg nivolumab at day 1 and 15). A complete clinical response was documented at day 21 after start of treatment. The patient underwent a total mesorectal excision at day 30. In the extirpated tissue, a complete pathological response was confirmed. Conclusion: In MSI-H/dMMR locally advanced rectal cancer short-course ICI treatment is highly effective and may be discussed in patients with dMMR locally advanced rectal cancer.
Background: To analyze postoperative, in-hospital, complication rates in patients with organ transplantation before radical prostatectomy (RP). Methods: From National Inpatient Sample (NIS) database (2000–2015) prostate cancer patients treated with RP were abstracted and stratified according to prior organ transplant versus nontransplant. Multivariable logistic regression models predicted in-hospital complications. Results: Of all eligible 202,419 RP patients, 216 (0.1%) underwent RP after prior organ transplantation. Transplant RP patients exhibited higher proportions of Charlson comorbidity index ≥2 (13.0% vs. 3.0%), obesity (9.3% vs. 5.6%, both p < 0.05), versus to nontransplant RP. Of transplant RP patients, 96 underwent kidney (44.4%), 44 heart (20.4%), 40 liver (18.5%), 30 (13.9%) bone marrow, <11 lung (<5%), and <11 pancreatic (<5%) transplantation before RP. Within transplant RP patients, rates of lymph node dissection ranged from 37.5% (kidney transplant) to 60.0% (bone marrow transplant, p < 0.01) versus 51% in nontransplant patients. Regarding in-hospital complications, transplant patients more frequently exhibited, diabetic (31.5% vs. 11.6%, p < 0.001), major (7.9% vs. 2.9%) cardiac complications (3.2% vs. 1.2%, p = 0.01), and acute kidney failure (5.1% vs. 0.9%, p < 0.001), versus nontransplant RP. In multivariable logistic regression models, transplant RP patients were at higher risk of acute kidney failure (odds ratio [OR]: 4.83), diabetic (OR: 2.81), major (OR: 2.39), intraoperative (OR: 2.38), cardiac (OR: 2.16), transfusion (OR: 1.37), and overall complications (1.36, all p < 0.001). No in-hospital mortalities were recorded in transplant patients after RP. Conclusions: Of all transplants before RP, kidney ranks first. RP patients with prior transplantation have an increased risk of in-hospital complications. The highest risk, relative to nontransplant RP patients appears to acute kidney failure.
The majority of excitatory synapses terminating on cortical neurons are found on dendritic spines. The geometry of spines, in particular the size of the spine head, tightly correlates with the strength of the excitatory synapse formed with the spine. Under conditions of synaptic plasticity, spine geometry may change, reflecting functional adaptations. Since the cytokine tumor necrosis factor (TNF) has been shown to influence synaptic transmission as well as Hebbian and homeostatic forms of synaptic plasticity, we speculated that TNF-deficiency may cause concomitant structural changes at the level of dendritic spines. To address this question, we analyzed spine density and spine head area of Alexa568-filled granule cells in the dentate gyrus of adult C57BL/6J and TNF-deficient (TNF-KO) mice. Tissue sections were double-stained for the actin-modulating and plasticity-related protein synaptopodin (SP), a molecular marker for strong and stable spines. Dendritic segments of TNF-deficient granule cells exhibited ∼20% fewer spines in the outer molecular layer of the dentate gyrus compared to controls, indicating a reduced afferent innervation. Of note, these segments also had larger spines containing larger SP-clusters. This pattern of changes is strikingly similar to the one seen after denervation-associated spine loss following experimental entorhinal denervation of granule cells: Denervated granule cells increase the SP-content and strength of their remaining spines to homeostatically compensate for those that were lost. Our data suggest a similar compensatory mechanism in TNF-deficient granule cells in response to a reduction in their afferent innervation.
Aim: It can be challenging to distinguish COVID-19 in children from other common infections. We set out to determine the rate at which children consulting a primary care paediatrician with an acute infection are infected with SARS-CoV-2 and to compare distinct findings. Method: In seven out-patient clinics, children aged 0–13 years with any new respiratory or gastrointestinal symptoms and presumed infection were invited to be tested for SARS-CoV-2. Factors that were correlated with testing positive were determined. Samples were collected from 25 January 2021 to 01 April 2021. Results: Seven hundred and eighty-three children participated in the study (median age 3 years and 0 months, range 1 month to 12 years and 11 months). Three hundred and fifty-eight were female (45.7%). SARS-CoV-2 RNA was detected in 19 (2.4%). The most common symptoms in children with as well as without detectable SARS-CoV-2 RNA were rhinitis, fever and cough. Known recent exposure to a case of COVID-19 was significantly correlated with testing positive, but symptoms or clinical findings were not. Conclusion: COVID-19 among the children with symptoms of an acute infection was uncommon, and the clinical presentation did not differ significantly between children with and without evidence of an infection with SARS-CoV-2.
Introduction: Adeno-associated virus (AAV)-based gene therapy for haemophilia presents a challenge to the existing structure of haemophilia centres and requires a rethink of current collaboration and information exchange with the aim of ensuring a system that is fit-for-purpose for advanced therapies to maximise benefits and minimise risks. In Europe, a certification process based on the number of patients and facilities is offered to the haemophilia centres by European Haemophilia Network (EUHANET). Aim and methods: This joint European Association for Haemophilia and Allied Disorders (EAHAD) and European Haemophilia Consortium (EHC) publication describes criteria for centres participating in gene therapy care that require a reassessment of the infrastructure of comprehensive care and provides an outlook on how these criteria can be implemented in the future work of haemophilia centres. Results: The core definition of a haemophilia treatment centre remains, but additional roles could be implemented. A modifiable ‘hub-and-spoke’ model addresses all aspects associated with gene therapy, including preparation and administration of the gene therapy product, determination of coagulation and immunological parameters, joint.
Introduction: Over the last decade, multiple clinical trials demonstrated improved survival after chemotherapy for metastatic prostate cancer (mPCa). However, real-world data validating this effect within large-scale epidemiological data sets are scarce. We addressed this void. Materials and Methods: Men with de novo mPCa were identified and systemic chemotherapy status was ascertained within the Surveillance, Epidemiology, and End Results database (2004–2016). Patients were divided between historical (2004–2013) versus contemporary (2014–2016). Chemotherapy rates were plotted over time. Kaplan–Meier plots and Cox regression models with additional multivariable adjustments addressed overall and cancer-specific mortality. All tests were repeated in propensity-matched analyses. Results: Overall, 19,913 patients had de novo mPCa between 2004 and 2016. Of those, 1838 patients received chemotherapy. Of 1838 chemotherapy-exposed patients, 903 were historical, whereas 905 were contemporary. Chemotherapy rates increased from 5% to 25% over time. Median overall survival was not reached in contemporary patients versus was 24 months in historical patients (hazard ratio [HR]: 0.55, p < 0.001). After propensity score matching and additional multivariable adjustment (age, prostate-specific antigen, GGG, cT-stage, cN-stage, cM-stage, and local treatment) a HR of 0.55 (p < 0.001) was recorded. Analyses were repeated for cancer-specific mortality after adjustment for other cause mortality in competing risks regression models and recorded virtually the same findings before and after propensity score matching (HR: 0.55, p < 0.001). Conclusions: In mPCa patients, chemotherapy rates increased over time. A concomitant increase in survival was also recorded.
Purpose: To evaluate the impact of testing asymptomatic cancer patients, we analyzed all tests for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) before and during radiotherapy at a tertiary cancer center throughout the second wave of the pandemic in Germany. Methods: Results of all real-time polymerase chain reaction (RT-PCR) tests for SARS-CoV 2 performed at our radio-oncology department between 13 October 2020 and 11 March 2021 were included. Clinical data and anamnestic information at the time of testing were documented and examined for (i) the presence of COVID-19-related symptoms and (ii) virus-related anamnesis (high-risk [prior positive test or contact to a positive tested person within the last 14 days] or low-risk [inconspicuous anamnesis within the last 14 days]). Results: A total of 1056 SARS-CoV 2 tests in 543 patients were analyzed. Of those, 1015 tests were performed in asymptomatic patients and 41 tests in patients with COVID-19-associated symptoms. Two of 940 (0.2%) tests in asymptomatic patients with low-risk anamnesis and three of 75 (4.0%) tests in asymptomatic patients with high-risk anamnesis showed a positive result. For symptomatic patients, SARS-CoV 2 was detected in three of 36 (8.3%) low-risk and three of five (60.0%) high-risk tests. Conclusion: To the best of our knowledge, this is the first study evaluating the correlation between individual risk factors and positivity rates of SARS-CoV 2 tests in cancer patients. The data demonstrate that clinical and anamnestic assessment is a simple and effective measure to distinctly increase SARS-CoV 2 test efficiency. This might enable cancer centers to adjust test strategies in asymptomatic patients, especially when test resources are scarce.
Interpretation bias and dysfunctional social assumptions are proposed to play a pivotal role in the development and maintenance of social phobia (SP), especially in youth. In this study, we aimed to investigate disorder-specific implicit assumptions of rejection and implicit interpretation bias in youth with severe, chronic SP and healthy controls (CG). Twenty-seven youth with SP in inpatient/day-care treatment (M age = 15.6 years, 74% female) and 24 healthy controls (M age = 15.7 years, 54% female) were included. The Implicit Association Test (IAT) and the Affect Misattribution Procedure (AMP) were completed to assess implicit assumptions and interpretation bias related to the processing of social and affective stimuli. No group differences were observed for the IAT controlling for depressive symptoms in the analyses. However, group differences were found regarding interpretation bias (p = .017, η2p = .137). Correlations between implicit scores and explicit questionnaire results were medium to large in the SP group (r =|.28| to |.54|, pall ≤ .05), but lower in the control group (r =|.04| to |.46|, pall ≤ .05). Our results confirm the finding of an interpretation bias in youth SP, especially regarding the implicit processing of faces, whereas implicit dysfunctional social assumptions of being rejected do not seem to be specific for SP. Future research should investigate the causal relationship of assumptions/interpretation bias and SP.
Estimating the age of the developmental stages of the blow fly Calliphora vicina (Diptera: Calliphoridae) is of forensic relevance for the determination of the minimum post-mortem interval (PMImin). Fly eggs and larvae can be aged using anatomical and morphological characters and their modification during development. However, such methods can only hardly be applied for aging fly pupae. Previous study described age estimation of C. vicina pupae using gene expression, but just when reared at constant temperatures, but fluctuating temperatures represent a more realistic scenario at a crime scene. Therefore, age-dependent gene expression of C. vicina pupae were compared at 3 fluctuating and 3 constant temperatures, the latter representing the mean values of the fluctuating profiles. The chosen marker genes showed uniform expression patterns during metamorphosis of C. vicina pupae bred at different temperature conditions (constant or fluctuating) but the same mean temperature (e.g. constant 10 °C vs. fluctuating 5–15 °C). We present an R-based statistical tool, which enables estimation of the age of the examined pupa based on the analysed gene expression data.
The physiotherapist plays an essential role for people with haemophilia, an inherited bleeding disease responsible for musculoskeletal complications. Yet, with the advent of new and advanced therapies, the medical landscape is changing, and physiotherapy must adapt alongside. This paper considers whether there will still be a need for physiotherapy in the era of advanced therapies, and discusses ways in which services should evolve to complement emerging treatment paradigms for haemostasis in people with haemophilia. Ultimately, physiotherapy will remain an important element of care, even for people with little joint damage and low risks in the era of the new mild phenotype. However, competencies will need to evolve, and physiotherapists in both primary care and specialist treatment centres should work with haematology colleagues to develop more sensitive tools for detecting early joint changes. Physiotherapists will also play a crucial role in counselling and physically coaching, monitoring the musculoskeletal status of people with haemophilia who have transitioned to new treatments.
Given the ongoing global SARS-CoV-2-vaccination efforts, clinical awareness needs to be raised regarding the possibility of an increased incidence of SARS-CoV-2-vaccine-related immune-mediated thrombocytopenia in patients with intracerebral hemorrhage (ICH) secondary to cerebral sinus and vein thrombosis (CVT) requiring (emergency) neurosurgical treatment in the context of vaccine-induced immune thrombotic thrombocytopenia (VITT). Only recently, an association of vaccinations and cerebral sinus and vein thrombosis has been described. In a number of cases, neurosurgical treatment is warranted for these patients and special considerations are warranted when addressing the perioperative coagulation. We, herein, describe the past management of patients with VITT and established a literature-guided algorithm for the treatment of patients when addressing the impaired coagulation in these patients. Increasing insights addressing the pathophysiology of SARS-CoV-2-vaccine-related immune-mediated thrombocytopenia guide physicians in developing an interdisciplinary algorithm taking into account the special considerations of this disease.
Background: Both selective mutism (SM) and social anxiety disorder (SAD) are severe pediatric anxiety disorders with the common trait of behavioral inhibition (BI). The underlying pathophysiology of these disorders remains poorly understood, however converging evidence suggests that alterations in several peripheral molecular pathways might be involved. In a pilot study, we investigated alterations in plasma molecular markers (dipeptidyl peptidase-4 [DPPIV], interleukin-6 [IL-6], tumor necrosis factor-β [TNF-β] and neuropeptide-Y [NPY]) in children with SM, SAD, and healthy controls, as well as the correlation of these markers to symptom severity. Methods: We included 51 children and adolescents (aged 5–18 years; n = 29 girls): n = 20 children in the SM-, n = 16 in the SAD- and n = 15 in the control-group (CG). Peripheral blood samples were analyzed for DPPIV, IL-6, TNF-β, and NPY concentrations. Diverse psychometric measures were used for BI, anxiety, and mutism symptoms. Results: Lower DPPIV-levels were correlated with more anxiety symptoms. However, we could not find a difference in any molecular marker between the patients with SAD and SM in comparison to the CG. Conclusion: DPPIV is proposed as relevant marker for child and adolescent anxiety. Investigating the pathophysiology of SM and SAD focusing on state and trait variables as anxiety or BI might help better understanding the underlying mechanisms of these disorders. Further studies with especially larger cohorts are needed to validate the current pilot-findings.
Since the survival rates of pediatric patients undergoing cancer treatment or hematopoietic stem cell transplantation (HSCT) have increased rapidly in recent decades, the late effects of treatment are now an important focus of patient care. Access to fertility preservation (FP) procedures as well as their financing differs considerably across Europe. However, some countries in Europe have recently changed the legal basis for financing FP procedures; therefore, the implementation of structures is mandatory to give patients access to FP. In this prospective cohort study, we characterized the process for establishing pediatric fertility counseling, including the development of an in-house standard procedure for recommendations regarding FP with potentially gonadotoxic treatment and valuating data from all FP counseling sessions. All data concerning patient characteristics (pubertal status, disease group) and recommendation of FP measures were prospectively collected and adoption of FP measures analyzed. Prior to the establishment of a structured process for FP in our pediatric oncology and stem cell transplantation center, there was no standardized FP counseling. We demonstrate that with the establishment of an inhouse standard procedure, it is possible to give consistent yet individualized FP counseling to approximately 90% of our patients facing gonadotoxic treatment, counseling over 200 patients between 2017 and 2019. This pilot study could potentially be adapted in other pediatric hematology, oncology, and stem cell transplantation centers to allow a more standardized handling of FP counseling for all patients facing gonadotoxic treatment.
Purpose: To investigate short-term (3 months follow-up) changes in visual quality following Descemet membrane endothelial keratoplasty (DMEK) for Fuchs endothelial dystrophy (FED). Methods: In this prospective institutional case series, 51 patients that underwent DMEK for FED were included. Assessment included the Quality of Vision (QoV) questionnaire preoperatively, at 1 month, and 3 months after surgery. Secondary outcome measures were anterior segment parameters acquired by Scheimpflug imaging, corrected distance visual acuity (CDVA), and endothelial cell density (ECD). Results: Glare, hazy vision, blurred vision, and daily fluctuation in vision were the symptoms mostly reported preoperatively. All symptoms demonstrated a significant reduction of item scores for severity, frequency, and bothersome in the course after DMEK (P < 0.01). Glare and fluctuation in vision remained to some extent during the follow-up period (median score = 1). Preoperatively, corneal densitometry correlated moderately to weakly with severity of hazy vision (rs = 0.39; P = 0.03) and frequency (rs = 0.26; P = 0.02) as well as severity (rs = 0.27; P = 0.03) of blurry vision. CDVA and central corneal thickness (CCT) did not correlate with visual complains. Conclusions: Following DMEK for FED, patient-reported visual symptoms assessed by the QoV questionnaire represent a useful tool providing valuable information on the impact of DMEK on visual quality that cannot be directly estimated by morphological parameters and visual acuity only.
Background: SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylated forms. Hence, SAMHD1 inhibitors are promising candidates for the sensitisation of leukaemia cells to nucleoside analogue-based therapy. Here, we investigated the effects of the cytosine analogue CNDAC, which has been proposed to be a SAMHD1 inhibitor, in the context of SAMHD1. Methods: CNDAC was tested in 13 acute myeloid leukaemia (AML) cell lines, in 26 acute lymphoblastic leukaemia (ALL) cell lines, ten AML sublines adapted to various antileukaemic drugs, 24 single cell-derived clonal AML sublines, and primary leukaemic blasts from 24 AML patients. Moreover, 24 CNDAC-resistant sublines of the AML cell lines HL-60 and PL-21 were established. The SAMHD1 gene was disrupted using CRISPR/Cas9 and SAMHD1 depleted using RNAi, and the viral Vpx protein. Forced DCK expression was achieved by lentiviral transduction. SAMHD1 promoter methylation was determined by PCR after treatment of genomic DNA with the methylation-sensitive HpaII endonuclease. Nucleoside (analogue) triphosphate levels were determined by LC-MS/MS. CNDAC interaction with SAMHD1 was analysed by an enzymatic assay and by crystallisation. Results: Although the cytosine analogue CNDAC was anticipated to inhibit SAMHD1, SAMHD1 mediated intrinsic CNDAC resistance in leukaemia cells. Accordingly, SAMHD1 depletion increased CNDAC triphosphate (CNDAC-TP) levels and CNDAC toxicity. Enzymatic assays and crystallisation studies confirmed CNDAC-TP to be a SAMHD1 substrate. In 24 CNDAC-adapted acute myeloid leukaemia (AML) sublines, resistance was driven by DCK (catalyses initial nucleoside phosphorylation) loss. CNDAC-adapted sublines displayed cross-resistance only to other DCK substrates (e.g. cytarabine, decitabine). Cell lines adapted to drugs not affected by DCK or SAMHD1 remained CNDAC sensitive. In cytarabine-adapted AML cells, increased SAMHD1 and reduced DCK levels contributed to cytarabine and CNDAC resistance. Conclusion: Intrinsic and acquired resistance to CNDAC and related nucleoside analogues are driven by different mechanisms. The lack of cross-resistance between SAMHD1/ DCK substrates and non-substrates provides scope for next-line therapies after treatment failure.
Cancer therapies have experienced significant advances in recent years. While conventional cytotoxic chemotherapy has long been the cornerstone for the treatment of many tumor entities, uprising immunotherapies have revolutionized the therapeutic landscape. Among them, immune checkpoint inhibitors (ICIs) with their demonstrated increased overall survival rates and response rates in cancer patients are now FDA-approved for metastatic melanoma and multiple other malignancies. Despite their clinical benefit in cancer therapies, ICIs can induce unique autoimmune-like toxicities known as immune-related adverse events (irAEs), which can involve any organ system including the nervous system. Although neurotoxicities are rare complications of ICI therapy they are often severe and can lead to long-term disability or even death if left untreated.
Neurological irAEs exhibit a broad spectrum of clinical presentations affecting the entire nervous system. Diagnosing neurological irAEs is often challenging as symptoms and laboratory findings can be uncharacteristic for common neurological disorders and clinical experience with ICI-mediated toxicities is still limited. In light of expanding clinical indications for ICIs, physicians will encounter ICI-mediated neurotoxicities more frequently. Thus, thorough characterizations of the diverse set of neurological irAEs are essential for optimal patient care, the prevention of severe ICI-mediated complications, and the development of diagnostic and therapeutic algorithms. This work portrays the clinical presentation, management and outcome of neurological irAEs following ICI therapies.
Patients with neurotoxicities related to ICIs who presented at the Yale New Haven Hospital between January 2014 and June 2018 were retrospectively identified from the quality control database. A comprehensive chart review was performed and data regarding patient demographics, medical history, ICI regimen and neurotoxicity were recorded. In total, 18 patients with neurological irAEs following ICI therapy for melanoma, small cell lung cancer, non-small cell lung cancer, and Merkel-cell carcinoma were identified. Neurotoxicities included central nervous system disorders comprising central demyelinating disorder,autoimmune encephalitis predominantly affecting the grey matter, and aseptic meningitis. Peripheral nervous system toxicities included sensorimotor polyneuropathy and myasthenia gravis. Cases of hypophysitis were also recorded. Time to onset of neurological irAEs ranged from 1 to72 weeks with a median of five weeks. In all patients ICIs were held and steroids initiated. Additional immunomodulatory therapies were required in nine patients. Sixteen of 18 patients showed neurological improvement. Fourteen patients had highgrade neurotoxicity (grade 3-4), six of whom deceased due to cancer progression, while none of the low-grade neurotoxicity patients (grade 1-2) died. High-grade neurotoxicity was identified as a negative prognostic marker for overall survival (p = 0.046).
This work shows that neurotoxicities present early-onset, rapidly progressive complications of ICIs with a broad spectrum of clinical phenotypes affecting the central nervous system, peripheral nervous system, and neuroendocrine system. A high index of caution for neurological irAEs is warranted throughout ICI therapy as timely diagnosis and management can reduce morbidity and mortality. Randomized clinical trials are needed to develop standardized diagnostic and therapeutic algorithms of ICI-induced neurotoxicities.
Transcatheter left atrial appendage occlusion (LAAO) is non-inferior to vitamin K antagonists (VKAs) in preventing thromboembolic events in atrial fibrillation (AF). Non-vitamin K antagonists (NOACs) have an improved safety profile over VKAs; however, evidence regarding their effect on cardiovascular and neurological outcomes relative to LAAO is limited. Up-to-date randomized trials or propensity-score-matched data comparing LAAO vs. NOACs in high-risk patients with AF were pooled in our study. A total of 2849 AF patients (LAAO: 1368, NOACs: 1481, mean age: 75 ± 7.5 yrs, 63.5% male) were enrolled. The mean CHA2DS2-VASc score was 4.3 ± 1.7, and the mean HAS-BLED score was 3.4 ± 1.2. The baseline characteristics were comparable between the two groups. In the LAAO group, the success rate of device implantation was 98.8%. During a mean follow-up of 2 years, as compared with NOACs, LAAO was associated with a significant reduction of ISTH major bleeding (p = 0.0002). There were no significant differences in terms of ischemic stroke (p = 0.61), ischemic stroke/thromboembolism (p = 0.63), ISTH major and clinically relevant minor bleeding (p = 0.73), cardiovascular death (p = 0.63), and all-cause mortality (p = 0.71). There was a trend toward reduction of combined major cardiovascular and neurological endpoints in the LAAO group (OR: 0.84, 95% CI: 0.64–1.11, p = 0.12). In conclusion, for high-risk AF patients, LAAO is associated with a significant reduction of ISTH major bleeding without increased ischemic events, as compared to “contemporary NOACs”. The present data show the superior role of LAAO over NOACs among high-risk AF patients in terms of reduction of major bleeding; however, more randomized controlled trials are warranted.
Simple Summary: The role of transcriptionally deregulated miRNAs (microRNAs) in classical Hodgkin lymphoma (cHL) is still not fully understood. To address this issue, we have performed global miRNA expression profiling of commonly used cHL cell lines and we present a complete cHL miRNome (microRNome). Within this group, we identify miRNAs recurrently deregulated in cHL cell lines, and compare them to non-Hodgkin lymphoma cell lines and sorted normal CD77+ germinal centre B-cells. Moreover, we show that several of the recurrently overexpressed miRNAs in cHL cell lines, and also primary microdissected HRS (Hodgkin and Reed-Sternberg) cells, target known B-cell-related transcription factors and NF-κB inhibitors. These findings provide evidence that deregulated miRNAs contribute to the loss of B-cell phenotype and NF-κB activation observed in this lymphoma.
Abstract: A hallmark of classical Hodgkin lymphoma (cHL) is the attenuation of B-cell transcription factors leading to global transcriptional reprogramming. The role of miRNAs (microRNAs) involved in this process is poorly studied. Therefore, we performed global miRNA expression profiling using RNA-seq on commonly used cHL cell lines, non-Hodgkin lymphoma cell lines and sorted normal CD77+ germinal centre B-cells as controls and characterized the cHL miRNome (microRNome). Among the 298 miRNAs expressed in cHL, 56 were significantly overexpressed and 23 downregulated (p < 0.05) compared to the controls. Moreover, we identified five miRNAs (hsa-miR-9-5p, hsa-miR-24-3p, hsa-miR-196a-5p, hsa-miR-21-5p, hsa-miR-155-5p) as especially important in the pathogenesis of this lymphoma. Target genes of the overexpressed miRNAs in cHL were significantly enriched (p < 0.05) in gene ontologies related to transcription factor activity. Therefore, we further focused on selected interactions with the SPI1 and ELF1 transcription factors attenuated in cHL and the NF-ĸB inhibitor TNFAIP3. We confirmed the interactions between hsa-miR-27a-5p:SPI1, hsa-miR-330-3p:ELF-1, hsa-miR-450b-5p:ELF-1 and hsa-miR-23a-3p:TNFAIP3, which suggest that overexpression of these miRNAs contributes to silencing of the respective genes. Moreover, by analyzing microdissected HRS cells, we demonstrated that these miRNAs are also overexpressed in primary tumor cells. Therefore, these miRNAs play a role in silencing the B-cell phenotype in cHL.
Preeclampsia (PE), a gestational hypertensive disease originating from the placenta, is characterized by an imbalance of various cellular processes. The cell cycle regulator p21Cip1/CDKN1A (p21) and its family members p27 and p57 regulate signaling pathways fundamental to placental development. The aim of the present study was to enlighten the individual roles of these cell cycle regulators in placental development and their molecular involvement in the pathogenesis of PE. The expression and localization of p21, phospho-p21 (Thr-145), p27, and p57 was immunohistochemically analyzed in placental tissues from patients with early-onset PE, early-onset PE complicated by the HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome as well as late-onset PE compared to their corresponding control tissues from well-matched women undergoing caesarean sections. The gene level was evaluated using real-time quantitative PCR. We demonstrate that the delivery mode strongly influenced placental gene expression, especially for CDKN1A (p21) and CDKN1B (p27), which were significantly upregulated in response to labor. Cell cycle regulators were highly expressed in first trimester placentas and impacted by hypoxic conditions. In support of these observations, p21 protein was abundant in trophoblast organoids and hypoxia reduced its gene expression. Microarray analysis of the trophoblastic BeWo cell line depleted of p21 revealed various interesting candidate genes and signaling pathways for the fusion process. The level of p21 was reduced in fusing cytotrophoblasts in early-onset PE placentas and depletion of p21 led to reduced expression of fusion-related genes such as syncytin-2 and human chorionic gonadotropin (β-hCG), which adversely affected the fusion capability of trophoblastic cells. These data highlight that cell cycle regulators are important for the development of the placenta. Interfering with p21 influences multiple pathways related to the pathogenesis of PE.